

- 1 -

A METHOD OF NUCLEAR TRANSFERFIELD OF THE INVENTION

5 The present invention relates to nuclear transfer methods and embryos developed therefrom. Methods of culturing embryos and reconstituting animals from the embryos generated by the nuclear transfer methods of the present invention are also included.

10 BACKGROUND OF THE INVENTION

The potential benefits of nuclear transfer have been reviewed recently in a number of publications (Galli et al., 1999; Colman, 1999; Wells & Powell, 2000; Lewis et al., 2001; Trounson, 2001). Methods for nuclear transfer  
15 have been sought and developed in earnest over the past two decades and are described in many references (See, for example, Campbell et al., Theriogenology, 43: 181 (1995); Collas et al., Mol. Reprod. Dev., 38: 264-267 (1994); Keefer et al., Biol. Reprod., 50: 935-939 (1994); Sims et  
20 al., Proc. Natl. Acad. Sci., USA, 90: 6143-6147 (1993); WO97/07668; WO97/07669; WO94/26884; WO94/24274; as well as U.S. Pat. Nos. 4,944,384 and 5,057,420 (which describe bovine nuclear transplantation), all of which are incorporated in their entirety herein by reference.

25 Briefly, methods for nuclear transfer typically include the steps of: (1) enucleating an oocyte; (2) isolating a donor cell or nucleus to be combined with the enucleated oocyte; (3) inserting the cell or nucleus into the enucleated oocyte to form a reconstituted cell; (4)  
30 implanting the reconstituted cell into the womb of an animal to form an embryo; and (5) allowing the embryo to develop.

Oocytes are generally retrieved from deceased animals, although they may be isolated also from either  
35 oviducts and/or ovaries of live animals. Oocytes are typically matured in a variety of medium known to those of ordinary skill in the art prior to enucleation.

- 2 -

Enucleation of the oocyte can be performed in a number of manners well known to those of ordinary skill in the art.

Insertion of the donor cell or nucleus into the enucleated oocyte to form a reconstituted cell is usually  
5 by microinjection of a donor cell under the zona pellucida prior to fusion. Fusion may be induced by application of a DC electrical pulse across the contact/fusion plane (electrofusion), by exposure of the cells to fusion-promoting chemicals, such as polyethylene glycol, or by  
10 way of an inactivated virus, such as the Sendai virus.

A reconstituted cell is typically activated by electrical and/or non-electrical means before, during, and/or after fusion of the nuclear donor and recipient oocyte. Activation methods include electric pulses,  
15 chemically induced shock, penetration by sperm, increasing levels of divalent cations in the oocyte, and reducing phosphorylation of cellular proteins (as by way of kinase inhibitors) in the oocyte. The activated reconstituted cells, or embryos, are typically cultured in medium well  
20 known to those of ordinary skill in the art and then transferred to the womb of an animal.

Until recently, donor nuclei have been conventionally isolated almost entirely from primordial germ cells or embryonic cells. Indeed, until the late  
25 1990s it was widely believed that only embryonic or undifferentiated cell types could direct any sort of fetal development following nuclear transfer. As a consequence most of today's techniques used in nuclear transfer procedures were developed utilising embryonic cells as  
30 donor cells and enucleated oocytes as recipient cells.

Notwithstanding, the isolation and use of embryonic donor cells requires specialised skills and is very labour intensive. More importantly, embryonic donor cells are a limited source of genetic material for nuclear  
35 transfer methods and their manipulation *in vitro* to produce cells, embryos, and animals whose genomes have been manipulated (e.g., transgenic) is not possible.

- 3 -

In 1997 this situation changed when it was reported that successful nuclear transfers had been done using cultured cell lines as donors (See, for example, Wilmut et al., Nature (London) 385, 810-183) (1997).

5 Accordingly, with the advent of somatic cell nuclear transfer some of the problems with "traditional" embryonic cell nuclear transfer were solved. In particular, the limited source of genetic material was overcome. However, some problems still remain as not all techniques used in  
10 embryonic cell nuclear transfer can be readily utilised for somatic cell nuclear transfer. For example, due to the vastly different sizes of somatic cells compared to embryonic cells some of the techniques used traditionally are not readily adapted.

15 Indeed, the *in vitro* steps of the methods described above have low efficiency rates resulting in low pregnancy and calving rates, deaths after birth and developmental anomalies. The efficiency of live births from somatic cell nuclear transfer using the method  
20 described by Wilmut et al., (Wilmut et al., Nature 385: 810-183 (1997)) has been estimated to be approximately 1 out of 300, that is, the nuclear transfer efficiency is at best 0.4% (i.e. number of cloned lambs divided by the number of nuclear transfers used to produce that number of  
25 cloned lambs). More importantly, all of the methods described in the literature require highly skilled technicians and costly equipment. In order for the widespread practical application of nuclear transfer methods to become more commercially viable it is  
30 imperative that the cloning efficiency is increased, the costs associated with the methods decreased and the requirement for highly skilled technicians overcome.

Accordingly, despite the apparent establishment of many of the methods for somatic cell nuclear transfer  
35 there remain some major technical obstacles impeding the widespread practical application of these methods.

In an attempt to improve cloning efficiencies

- 4 -

many research groups have modified the nuclear transfer methods; however, these modifications still require costly equipment and/or skilled labour. For example, a critical step in the nuclear transfer method outlined above is step 5 3; the step of inserting the donor cell or nucleus into the enucleated oocyte. As discussed above, this step typically requires two procedures, firstly, the microinjection of a donor cell under the zona pellucida of an enucleated oocyte and then secondly, fusion. However, 10 the microinjection step impedes the commercialisation prospects of nuclear transfer as this requires specialised skills and equipment.

One technique that obviated the use of microinjection used previously in the more traditional 15 approach with oocytes and embryonic donor cells involved the removal of the zona pellucida. See, for example, WO98/29532 and Peura et al. (1998), both of which are incorporated herein by reference. Unfortunately, an intact zona pellucida is generally considered important in 20 somatic cell nuclear transfer for several reasons including (1) keeping the polar body close to the metaphase plate of the oocyte to indicate the appropriate site for enucleation, (2) keeping the donor cell close to the oocyte cytoplasm before and during fusion, (3) 25 providing protection for the pairs during fusion, and (4) supporting embryo development after reconstitution and activation. Accordingly, the technique of Peura et al. *supra* has not been successful used with somatic cells.

The presence of the zona pellucida during nuclear 30 transfer means that sophisticated micromanipulation tools and high skill levels are required. In order to bypass the zona pellucida micromanipulators are used to transfer the donor cell into the perivitelline space of an enucleated oocyte to produce the reconstituted cell.

35 Micromanipulators are specialised devices that require tool making equipment including capillary pullers, grinders and microforges. More importantly, the use of

- 5 -

the micromanipulators, and the equipment to make these, require skilled technicians. These requirements considerably limit the simplification needed for the large-scale application of nuclear transfer methods.

5           Based upon the foregoing, it can be seen that the benefits and prospects of somatic cell nuclear transfer procedures which provides for the use of donor cells which retain the ability to produce reconstituted cells capable of developing into viable animals and that  
10 provides for high cloning efficiency without the need for micromanipulators are considerable. Immediate consequences would include decreased costs of both equipment and labour, and would therefore lead to more cost effective cloned animal production.

15           To this end, the applicant has now developed a somatic cell nuclear transfer method which avoids the use of micromanipulators, thereby allowing for standard fusion techniques to be used, while maintaining or increasing cloning efficiency. In one embodiment, the method  
20 utilises zona pellucida-free, enucleated oocytes as recipients and somatic cells or nuclei as donors. To avoid unplanned embryo aggregation, the reconstituted zona pellucida-free embryos are cultured in specialised systems, either individually or as "aggregates" of two or  
25 three reconstituted nuclear transfer embryos, as conventional systems are inappropriate for the purpose.

#### SUMMARY OF THE INVENTION

In the broadest aspect of the invention there is  
30 provided a novel and improved method for producing cloned mammalian cells.

Accordingly, in a first aspect the invention provides a method of nuclear transfer comprising the step of transferring a somatic cell or somatic cell nuclei into  
35 a zona pellucida-free, enucleated oocyte.

In a second aspect the invention provides a method for producing genetically engineered or transgenic

- 6 -

mammals by which a desired gene is inserted, removed or modified in a somatic cell or cell nucleus prior to transferring the somatic cell or cell nucleus into a zona pellucida-free, enucleated oocyte.

5           The invention further provides a method for producing a genetically engineered or transgenic mammal comprising:

(i) inserting, removing or modifying a desired gene or genes in a somatic cell or cell nucleus;

10           (ii) inserting the somatic cell or cell nucleus into a zona pellucida-free, enucleated oocyte under conditions suitable for the formation of a reconstituted cell;

15           (iii) activating the reconstituted cell to form an embryo;

(iv) culturing said embryo until greater than the 2-cell developmental stage; and

20           (v) transferring said cultured embryo to a host mammal such that the embryo develops into a transgenic fetus.

In a third aspect, the present invention provides a method for cloning a mammal comprising:

25           (i) inserting a desired somatic cell or cell nucleus into a zona pellucida-free, enucleated mammalian oocyte, under conditions suitable for the formation of a reconstituted cell;

(ii) activating the reconstituted cell to form an embryo;

30           (iii) culturing said embryo until greater than the 2-cell developmental stage; and

(iv) transferring said cultured embryo to a host mammal such that the embryo develops into a fetus.

35           Also provided by the present invention are mammals obtained according to the above method, and offspring of those mammals.

Oocytes may be isolated from any mammal by known procedures. For example, oocytes can be isolated from

- 7 -

either oviducts and/or ovaries of live animals by oviductal recovery procedures or transvaginal oocyte recovery procedures well known in the art and described herein. Furthermore, oocytes can be isolated from  
5 deceased animals. For example, ovaries can be obtained from abattoirs and the oocytes aspirated from these ovaries. The oocytes can also be isolated from the ovaries of a recently sacrificed animal or when the ovary has been frozen and/or thawed. Preferably, the oocytes are freshly  
10 isolated from the oviducts.

Oocytes or cytoplasts may also be cryopreserved before use.

While the methods described herein are useful for nuclear transfer in any mammal, it is particularly useful  
15 for ungulates. Preferably, the ungulate is selected from the group consisting of domestic or wild representatives of bovids, ovids, cervids, suids, equids and camelids. Examples of such representatives are cows or bulls, bison, buffalo, sheep, big-horn sheep, horses, ponies, donkeys,  
20 mule, deer, elk, caribou, goat, water buffalo, camels, llama, alpaca, and pigs. Especially preferred in the bovine species are *Bos taurus*, *Bos indicus*, and *Bos buffaloes* cows or bulls.

Removal of the zona pellucida can be accomplished  
25 by any known procedure. Preferably, the step of removing the zona pellucida is selected from the group consisting of physical manipulation, chemical treatment and enzymatic digestion. More preferably, the zona pellucida is removed by enzymatic digestion. Preferably, the enzyme used to  
30 digest the zona pellucida is a protease, a pronase or a combination thereof. More preferably, the enzyme is a pronase.

Preferably, the pronase is used at a concentration between 0.1 to 5%. More preferably, the  
35 concentration is between 0.25% to 2%. Most preferably, the pronase is at a concentration of about 0.5%.

It will be appreciated by those skilled in the

- 8 -

art that any procedure of enucleation of the oocyte can be performed, including, aspiration, physical removal, use of DNA-specific fluorochromes, and irradiation with ultraviolet light. Preferably, the enucleation is by physical means. Most preferable, the physical means is bisection.

Somatic cells are selected from the group consisting of epithelial cells, neural cells, epidermal cells, keratinocytes, hematopoietic cells, melanocytes, chondrocytes, lymphocytes (B and T lymphocytes), erythrocytes, macrophages, monocytes, mononuclear cells, fibroblasts, cardiac muscle cells, and other muscle cells.

These may be obtained from different organs, e.g., skin, lung, pancreas, liver, stomach, intestine, heart, reproductive organs, bladder, kidney, urethra and other urinary organs, etc.

Preferably, the somatic cells are fibroblast cells or granulosa cells. Most preferably, the somatic cells are *in vitro* cultured fibroblasts or granulosa cells.

Preferably, the step of transferring the somatic cell or nucleus is by fusion. More preferably, the method of fusion is selected from the group consisting of chemical fusion, electrofusion and biofusion. Preferably, the chemical fusion or biofusion is accomplished by exposing the zona pellucida-free, enucleated oocyte and somatic cell combination to a fusion agent. Preferably, the fusion agent is any compound or biological organism that can increase the probability that portions of plasma membranes from different cells will fuse when somatic cell donor is placed adjacent to the zona pellucida-free, enucleated oocyte recipient. Most preferably, the fusion agents are selected from the group consisting of polyethylene glycol (PEG), trypsin, dimethylsulfoxide (DMSO), lectins, agglutinin, viruses, and Sendai virus.

The electrofusion is preferably induced by application of an electrical pulse across the



- 9 -

contact/fusion plane. More preferably, the electrofusion comprises the step of delivering one or more electrical pulses to the zona pellucida-free, enucleated oocyte and somatic cell combination.

- 5           In a preferred embodiment, the method of the invention comprises a further step of increasing the cytoplasmic volume of a reconstituted cell by fusing the reconstituted cell with one or more oocyte(s).

          Accordingly, in a fourth aspect the present  
10 invention provides a method for cloning a mammal comprising:

- (i) inserting a desired somatic cell or cell nucleus into a first zona pellucida-free, enucleated mammalian oocyte, under conditions suitable for the  
15 formation of a reconstituted cell;
  - (ii) fusing a second oocyte to said reconstituted cell thereby increasing the cytoplasmic volume;
  - (iii) activating the reconstituted cell to form  
20 an embryo;
  - (iv) culturing said embryo until greater than the 2-cell developmental stage; and
  - (v) transferring said cultured embryo to a host mammal such that the embryo develops into a fetus.
- 25           Steps (i) and (ii) may be undertaken separately or simultaneously.

          Alternatively, in one preferred embodiment, there is provided a method of culturing a reconstituted cell (embryo) comprising

- 30           (i) inserting a desired somatic cell or cell nucleus into a zona pellucida-free, enucleated mammalian oocyte, under conditions suitable for the formation of a reconstituted cell;
- (ii) activating the reconstituted cell
  - 35           (iii) incubating and culturing one or more of said cells until embryos of greater than 2 cells develop.
- Preferably, the embryos are cultured until

- 10 -

greater than 60 cells. More preferably, between 60 to 200 cells.

Preferably, two or more cells are cultured together, more preferably, two or three cells are cultured together.

In an alternative embodiment, single reconstituted cells are cultured until embryos of between 8 to 128 cells are produced and then 2 or more embryos are combined and cultured together as aggregates.

Culturing zona pellucida-free nuclear transfer embryos as aggregates, increases the cell numbers in the final embryos for transfer and increases pregnancy rates.

Also provided by the present invention are mammals obtained according to the above methods, and offspring of those mammals.

#### BRIEF DESCRIPTION OF THE FIGURES

Figure 1 shows the results of a preferred method according to the present invention. The procedure and result of zona pellucida-free, oocyte-somatic cell transfer is provided. Panel A shows oocytes aligned in a petri dish prior to bisection. Panel B shows manual bisection of oocytes to produce enucleated oocytes (cytoplasts) and karyoplasts. Panel C shows enucleated oocyte and somatic cell prior to attachment. Panel D shows enucleated oocyte-somatic cell after attachment, prior to fusion. Panel E shows enucleated oocyte-somatic cell pair aligned on the electrofusion wire for the first fusion. Panel F shows unfused enucleated oocytes and fused enucleated oocyte-somatic cell pairs aligned to the electrofusion wire for the second fusion. Panel G shows blastocyst developed in the GO system 7 days after fusion. Panel H shows the same blastocyst after removal from the GO system.

#### DETAILED DESCRIPTION OF THE INVENTION

The practice of the present invention employs,

- 11 -

unless otherwise indicated, conventional molecular biology, cellular biology, and cloning techniques within the skill of the art. Such techniques are well known to the skilled worker, and are explained fully in the literature. See, for example, Sambrook and Russell "Molecular Cloning: A Laboratory Manual" (2001); Cloning: A Practical Approach," Volumes I and II (D.N. Glover, ed., 1985); "Antibodies: A Laboratory Manual" (Harlow & Lane, eds., 1988); "Animal Cell Culture" (R.I. Freshney, ed., 1986); "Immobilised Cells and Enzymes" (IRL Press, 1986).

Before the present methods are described, it is understood that this invention is not limited to the particular materials and methods described, as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims. It must be noted that as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, a reference to "a somatic cell" includes a plurality of such cells, and a reference to "an oocyte" is a reference to one or more oocytes, and so forth. Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any materials and methods similar or equivalent to those described herein can be used to practice or test the present invention, the preferred materials and methods are now described.

All publications mentioned herein are cited for the purpose of describing and disclosing the protocols, reagents and vectors which are reported in the publications and which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate

- 12 -

such disclosure by virtue of prior invention.

The present invention provides improved procedures for cloning mammals by nuclear transfer or nuclear transplantation. In the subject application, the terms "nuclear transfer" or "nuclear transplantation" are used interchangeably; however, these terms as used herein refers to introducing a full complement of nuclear DNA from one cell to an enucleated cell.

The first step in the preferred methods involves the isolation of a recipient oocyte from a suitable animal. In this regard, the oocyte may be obtained from any animal source and at any stage of maturation. Suitable mammalian sources include members of the Orders Primates, Rodentia, Lagomorpha, Cetacea, Carnivora, Perissodactyla and Artiodactyla. Members of the Orders Perissodactyla and Artiodactyla are particularly preferred because of their similar biology and economic importance.

For example, Artiodactyla comprises approximately 150 living species distributed through nine families: pigs (Suidae), peccaries (Tayassuidae), hippopotamuses (Hippopotamidae), camels (Camelidae), chevrotains (Tragulidae), giraffes and okapi (Giraffidae), deer (Cervidae), pronghorn (Antilocapridae), and cattle, sheep, goats and antelope (Bovidae). Many of these animals are used as feed animals in various countries. More importantly, with respect to the present invention, many of the economically important animals such as goats, sheep, cattle and pigs have very similar biology and share high degrees of genomic homology.

The Order Perissodactyla comprises horses and donkeys, which are both economically important and closely related. Indeed, it is well known that horses and donkeys interbreed.

In one embodiment, the oocytes will be obtained from ungulates, and in particular, bovids, ovids, cervids, suids, equids and camelids. Examples of such representatives are cows or bulls, bison, buffalo, sheep,

- 13 -

big-horn sheep, horses, ponies, donkeys, mule, deer, elk, caribou, goat, water buffalo, camels, llama, alpaca, and pigs. Especially preferred in the bovine species are *Bos taurus*, *Bos indicus*, and *Bos buffaloes* cows or bulls.

5               Methods for isolation of oocytes are well known in the art. For example, oocytes can be isolated from either oviducts and/or ovaries of live animals by oviductal recovery procedures or transvaginal oocyte recovery procedures well known in the art. See, for  
10               example, Pieterse et al., 1988, "Aspiration of bovine oocytes during transvaginal ultrasound scanning of the ovaries," *Theriogenology* 30: 751-762. Furthermore, oocytes can be isolated from ovaries or oviducts of  
15               deceased animals. For example, ovaries can be obtained from abattoirs and the oocytes aspirated from these  
                  ovaries. The oocytes can also be isolated from the ovaries of a recently sacrificed animal or when the ovary  
                  has been frozen and/or thawed.

                  Briefly, in one preferred embodiment, immature  
20               (prophase I) oocytes from mammalian ovaries are harvested by aspiration. For the successful use of techniques such as genetic engineering, nuclear transfer and cloning, once these oocytes have been harvested they must generally be  
                  matured *in vitro* before these cells may be used as  
25               recipient cells for nuclear transfer.

                  The stage of maturation of the oocyte at enucleation and nuclear transfer has been reported to be significant to the success of nuclear transfer methods. (See, for example, Prather et al., *Differentiation*, 48, 1-  
30               8, 1991). In general, successful mammalian embryo cloning practices use the metaphase II stage oocyte as the recipient oocyte because at this stage it is believed that the oocyte can be or is sufficiently activated to treat the introduced nucleus as it does a fertilising sperm.

35               The *in vitro* maturation of oocytes usually takes place in a maturation medium until the oocyte have extruded the first polar body, or until the oocyte has

- 14 -

attained the metaphase II stage. In domestic animals, and especially cattle, the oocyte maturation period generally ranges from about 16-52 hours, preferably about 28-42 hours and more preferably about 18-24 hours post-aspiration. For purposes of the present invention, this period of time is known as the "maturation period."

Oocytes can be matured in a variety ways and using a variety of media well known to a person of ordinary skill in the art. See, for example, U.S. Pat. No. 5,057,420; Saito et al., 1992, Roux's Arch. Dev. Biol. 201: 134-141 for bovine organisms and Wells et al., 1997, Biol. Repr. 57: 385-393 for ovine organisms and WO97/07668, entitled "Unactivated Oocytes as Cytoplasmic Recipients for Nuclear Transfer," all hereby incorporated herein by reference in the entirety, including all figures, tables, and drawings.

One of the most common media used for the collection and maturation of oocytes is Tissue Culture Medium-199 (TCM-199), and 1 to 20% serum supplement including fetal calf serum (FCS), newborn serum, estrual or non-estrual cow serum, lamb serum or steer serum. Example 1 of the present application shows one example of a preferred maintenance medium: TCM-199 with Earl salts supplemented with 15% cow serum and including 10IU/ml pregnant mare serum gonadotropin and 5IU/ml human chorionic gonadotropin (Suigonan<sup>R</sup> Vet, Intervet, Australia). Oocytes can be successfully matured in this type of medium within an environment comprising 5% CO<sub>2</sub> at 39°C.

While it will be appreciated by those skilled in the art that freshly isolated and matured oocytes are preferred, it will also be appreciated that it is possible to cryopreserve the oocytes after harvesting or after maturation. Accordingly, the term "cryopreserving" as used herein can refer to freezing an oocyte, cytoplasm, a cell, embryo, or animal of the invention. The oocytes, cytoplasm, cells, embryos, or portions of animals of the

- 15 -

invention are frozen at temperatures preferably lower than 0°C, more preferably lower than -80°C, and most preferably at temperatures lower than -196°C. Oocytes, cells and embryos of the invention can be cryopreserved for an indefinite amount of time. It is known that biological materials can be cryopreserved for more than fifty years. For example, semen that is cryopreserved for more than fifty years can be utilised to artificially inseminate a female bovine animal. Methods and tools for cryopreservation are well known to those skilled in the art. See, for example, U.S. Pat. No. 5,160,312, entitled "Cryopreservation Process for Direct Transfer of Embryos."

If cryopreserved oocytes are utilised then these must be initially thawed before placing the oocytes in maturation medium. Methods of thawing cryopreserved materials such that they are active after the thawing process are well-known to those of ordinary skill in the art.

In a further preferred embodiment, mature (metaphase II) oocytes, which have been matured *in vivo*, are harvested and used in the nuclear transfer methods disclosed herein. Essentially, mature metaphase II oocytes are collected surgically from either non-superovulated or superovulated mammals 35 to 48 hours past the onset of estrus or past the injection of human chorionic gonadotropin (hCG) or similar hormone.

Where oocytes have been cultured *in vitro* cumulus cells that may have accumulated may be removed to provide oocytes that are at a more suitable stage of maturation for enucleation. Cumulus cells may be removed by pipetting or vortexing, for example, in the presence of 0.5% hyaluronidase.

After the maturation period as described above the zona pellucida can then removed from the oocytes; however, in one particularly preferred embodiment, prior to the removal of the zona pellucida, the oocytes are placed in phosphate-buffered saline (PBS) containing

- 16 -

200 $\mu$ g/ml phytohemagglutinin (PHA) so that the polar body (PB) attaches to the oocyte. It has been shown that the chromosome containing metaphase plate is adjacent to the PB in over 90% of cases (Peura et al, 1998). After zona removal and oocyte bisection, the karyoplast (nucleus containing "half" of the bisected oocyte) can be easily identified and discarded.

The advantages of zona pellucida removal include providing a simpler, quicker and cheaper nuclear transfer method. In addition, the removal of the zona pellucida allows for large-scale production of nuclear transfer embryos. The removal of the zona pellucida from the oocyte may be carried out by any method known in the art including physical manipulation (mechanical opening), chemical treatment or enzymatic digestion (Wells and Powell, 2000). Physical manipulation may involve the use of a micropipette or a microsurgical blade. Preferably, enzymatic digestion is used.

In one particularly preferred embodiment, the zona pellucida is removed by enzymatic digestion in the presence of a protease or pronase. Briefly, mature oocytes are placed into a solution comprising a protease, pronase or combination of each at a total concentration in the range of 0.1% - 5%, more preferably 0.25% - 2% and most preferably about 0.5%. The mature oocyte is then allowed to incubate at between 30°C to about 45°C, preferably about 39°C for a period of 1 to 30 minutes. Preferably the oocytes are exposed to the enzyme for about 5 minutes. Although pronase may be harmful to the membranes of oocytes, this effect may be minimised by addition of serum such as FCS or cow serum. The unique advantage of zona pellucida removal with pronase is that no individual treatment is required, and the procedure can be performed in quantities of 100's of oocytes. Once the zona pellucida has been removed the zona pellucida-free mature oocyte may be rinsed in 4ml Hepes buffered TCM-199



- 17 -

medium supplemented with 20% FCS and 10µg/ml cytochalasin B and then enucleated.

The terms "enucleation", "enucleated" and "enucleated oocyte" are used interchangeably herein and refers to an oocyte which has had part of its contents removed.

Enucleation of the oocyte may be achieved physically, by actual removal of the nucleus, pronuclei or metaphase plate (depending on the oocyte), or functionally, such as by the application of ultraviolet radiation or another enucleating influence. All of these methods are well known to those of ordinary skill in the art. For example, physical means includes aspiration (Smith & Wilmut, Biol. Reprod., 40: 1027-1035 (1989)); functional means include use of DNA-specific fluorochromes (See, for example, Tusnoda et al., J. Reprod. Fertil. 82: 173 (1988)), and irradiation with ultraviolet light (See, for example, Gurdon, Q. J. Microsc. Soc., 101: 299-311 (1960)). Enucleation may also be effected by other methods known in the art. See, for example, U.S. Pat. No. 4,994,384; U.S. Pat. No. 5,057,420; and Willadsen, 1986, Nature 320:63-65, all of which are incorporated herein by reference.

Preferably, the oocyte is enucleated by means of manual bisection. Oocyte bisection may be carried out by any method known to those skilled in the art. In one preferred embodiment, the bisection is carried out using a microsurgical blade as described in WO98/29532 which is incorporated by reference herein. Briefly, oocytes are split asymmetrically into fragments representing approximately 30% and 70% of the total oocyte volume using an ultra sharp splitting blade (AB Technology, Pullman, WA, USA). The oocytes may then be screened to identify those of which have been successfully enucleated. This screening may be effected by selecting that bisected "half" with the polar body attached or by staining the oocytes with 1 microgram per millilitre of the Hoechst

- 18 -

fluorochrome 33342 dissolved in TCM-199 media supplemented with 20% FCS, and then viewing the oocytes under ultraviolet irradiation with an inverted microscope for less than 10 seconds. The oocytes that have been  
5 successfully enucleated (demi-oocytes) can then be placed in a suitable culture medium, eg., TCM-199 media supplemented with 20% FCS.

In the present invention, the recipient oocytes will preferably be enucleated at a time ranging from about  
10 10 hours to about 40 hours after the initiation of *in vitro* maturation, more preferably from about 16 hours to about 24 hours after initiation of *in vitro* maturation, and most preferably about 16-20 hours after initiation of *in vitro* maturation.

15 The bisection technique described herein requires much less time and skill than other methods of enucleation and the subsequent selection by staining results in high accuracy. Consequently, for large-scale application of cloning technology the present bisection technique can be  
20 more efficient than other techniques.

A single mammalian somatic cell of the same species as the enucleated oocyte can then be transferred by fusion into the enucleated oocyte thereby producing a reconstituted cell.

25 The term "somatic cell" as used herein is taken to mean any cell from an animal at any stage of development, other than an embryonic cell or germ cell.

According to the invention, cell nuclei derived from differentiated fetal or adult somatic cells are  
30 transferred into zona pellucida-free, enucleated oocytes of the same species as the donor nuclei. Differentiated somatic cells are those cells that are past the early embryonic stage. More particularly, the differentiated cells are those from at least past the embryonic disc  
35 stage (day 10 of bovine embryogenesis). The differentiated cells may be derived from ectoderm, mesoderm or endoderm.

Mammalian somatic cells may be obtained by well-

- 19 -

known methods. See, for example, U.S. Pat. No. 5,945,577, which teaches nuclear transfers from differentiated donor somatic cells to enucleated oocytes and U.S. Pat. No. 6,022,197, which teaches that fibroblasts from a  
5 fibroblast cell culture derived from an adult ear punch may be used as nuclear donors in a nuclear transfer process, both of these references are incorporated herein by reference.

It is preferred that the donor somatic cells of  
10 the present invention be induced to quiescence prior to fusion into the recipient zona pellucida-free, enucleated oocyte. In accordance with the teachings of PCT/GB96/02099 and WO97/07668, both assigned to the Roslin Institute (Edinburgh), it is preferred that the donor nucleus be in  
15 either the G0 or G1 phase of the cell cycle at the time of transfer. Donors must be diploid at the time of transfer in order to maintain correct ploidy of the reconstituted cell.

Mammalian somatic cells useful in the present  
20 invention include, by way of example, epithelial cells, neural cells, epidermal cells, keratinocytes, hematopoietic cells, melanocytes, chondrocytes, lymphocytes (B and T lymphocytes), erythrocytes, macrophages, monocytes, mononuclear cells, fibroblasts,  
25 cardiac muscle cells, and other muscle cells, etc. Moreover, the mammalian cells used for nuclear transfer may be obtained from different organs, eg., skin, lung, pancreas, liver, stomach, intestine, heart, reproductive organs, bladder, kidney, urethra and other urinary organs,  
30 etc. These are just examples of suitable donor cells. Suitable donor cells, ie., cells useful in the subject invention, may be obtained from any cell or organ of the body.

A particularly preferred donor cell is the  
35 fibroblast or fibroblast-like cell. Fibroblast cells are an ideal cell type because they can be obtained from developing fetuses and adult animals in large quantities.

- 20 -

Importantly, these cells can be easily propagated *in vitro* with a rapid doubling time and can be clonally propagated for use in gene targeting procedures.

Fibroblast cells may be collected from an ear  
5 skin biopsy and cut into small pieces (3mm<sup>2</sup>) and cultured. A variety of methods for culturing cells exist in the art. See, for example, *Culture of Animal Cells; A manual of Basic Technique* (2<sup>nd</sup>. edition), Freshney, copyright 1987, Alan R. Liss, Inc., New York. In one particularly  
10 preferred embodiment, explant cells from a skin biopsy are cultured in TCM-199 medium plus 20% FCS and antibiotics at 37°C, in a humidified atmosphere of 5% CO<sub>2</sub> and 95% air. After a week in culture, fibroblast cell monolayers form around the tissue explants. The explants are then removed  
15 to start new culture and the fibroblast cells are harvested by incubation with 0.05% trypsin for 5min. The trypsin is then inactivated by the addition of 800µl TCM-199 medium and 20% FCS. For long term storage, the cultured cells may be collected following trypsin  
20 treatment, frozen in 10% dimethyl sulfoxide and stored in liquid nitrogen. Upon use for nuclear transfer, cells are thawed and cultured to confluency for passage. For each passage (estimated 2 cell doublings per passage), cells are cultured until confluent, disaggregated by incubation  
25 in a 0.1% (w/v) trypsin and EDTA solution for 1 min at 37°C and allocated to three new flasks for further passaging. Normally, each passage lasts about 6 days.

Confirmation of fibroblast phenotype of donor cells may be conducted by immunocytochemical staining with  
30 monoclonal antibodies directed against the cytoskeletal filaments vimentin (for fibroblasts) or cytokeratin (for epithelial cells). In a preferred confirmation protocol, cells are grown to confluency. Cells are then washed with phosphate buffered saline (PBS) and fixed in methanol at  
35 4°C for 20 minutes. After fixation the cells are washed in PBS and blocked with 3% bovine serum albumin (BSA) in PBS for 15min at 37°C. The block is removed and 100µl of

- 21 -

either a 1:40 dilution anti-vimentin clone V9 (Sigma, cat#6630) or a 1:400 dilution of anti-pan cytokeratin clone-11 (Sigma, cat#2931) is added. Cells are incubated for 1h at 37°C, washed with PBS and incubated for 1h with  
5 100µl of a 1:300 dilution of FITC-labelled anti-mouse IgG. Cells are washed in PBS, covered with 50% glycerol in PBS under a coverslip and observed by fluorescence microscopy. Appropriate controls for auto-fluorescence and secondary antibodies should be included.

10 Analysis of cell cycle stage may be performed as described in Kubota et al., PNAS 97: 990-995 (2000). Briefly, cell cultures at different passages are grown to confluency. After trypsinisation, cells are washed with TCM-199 medium plus 10% FCS and re-suspended to a  
15 concentration of  $5 \times 10^5$  cells/ml in 1ml PBS with glucose (6.1 mM) at 4°C. Cells are fixed overnight by adding 3ml of ice-cold ethanol. For nuclear staining, cells are then pelleted, washed with PBS and re-suspended in PBS containing 30µg/ml propidium iodide and 0.3mg/ml RNase A.  
20 Cells are allowed to incubate for 1h at room temperature in the dark before filtered through a 30µm mesh. Cells are then analyzed.

To examine the ploidy of the cultured somatic donor cells at various passages, chromosome counts may be  
25 determined at different passages of culture using standard preparation of metaphase spreads (See, for example, Kubota et al., PNAS 97: 990-995 (2000)).

Cultured donor cells may also be genetically altered by transgenic methods well-known to those of  
30 ordinary skill in the art. See, for example, Molecular Cloning a Laboratory Manual, 2nd Ed., 1989, Sambrook, Fritsch and Maniatis, Cold Spring Harbor Laboratory Press; U.S. Pat. No. 5,612,205; U.S. Pat. No. 5,633,067; EPO 264 166, entitled "Transgenic Animals Secreting Desired  
35 Proteins Into Milk"; WO94/19935, entitled "Isolation of Components of Interest From Milk"; WO93/22432, entitled "Method for Identifying Transgenic Pre-implantation

- 22 -

Embryos"; and WO95/175085, entitled "Transgenic Production of Antibodies in Milk," all of which are incorporated by reference herein in their entirety including all figures, drawings and tables. Any known method for inserting, deleting or modifying a desired gene from a mammalian cell may be used for altering the differentiated cell to be used as the nuclear donor. These procedures may remove all or part of a gene, and the gene may be heterologous. Included is the technique of homologous recombination, which allows the insertion, deletion or modification of a gene or genes at a specific site or sites in the cell genome.

Examples for modifying a target DNA genome by deletion, insertion, and/or mutation are retroviral insertion, artificial chromosome techniques, gene insertion, random insertion with tissue specific promoters, gene targeting, transposable elements and/or any other method for introducing foreign DNA or producing modified DNA/modified nuclear DNA. Other modification techniques include deleting DNA sequences from a genome and/or altering nuclear DNA sequences. Nuclear DNA sequences, for example, may be altered by site-directed mutagenesis.

The present invention can thus be used to provide adult mammals with desired genotypes. Multiplication of adult ungulates with proven genetic superiority or other desirable traits is particularly useful, including transgenic or genetically engineered animals, and chimeric animals. Furthermore, cell and tissues from the nuclear transfer fetus, including transgenic and/or chimeric fetuses, can be used in cell, tissue and organ transplantation.

Methods for generating transgenic cells typically include the steps of (1) assembling a suitable DNA construct useful for inserting a specific DNA sequence into the nuclear genome of a cell; (2) transfecting the DNA construct into the cells; (3) allowing random

- 23 -

insertion and/or homologous recombination to occur. The modification resulting from this process may be the insertion of a suitable DNA construct(s) into the target genome; deletion of DNA from the target genome; and/or  
5 mutation of the target genome.

DNA constructs can comprise a gene of interest as well as a variety of elements including regulatory promoters, insulators, enhancers, and repressors as well as elements for ribosomal binding to the RNA transcribed  
10 from the DNA construct.

DNA constructs can also encode ribozymes and anti-sense DNA and/or PNA. These examples are well known to a person of ordinary skill in the art and are not meant to be limiting.

15 Due to the effective recombinant DNA techniques available in conjunction with DNA sequences for regulatory elements and genes readily available in data bases and the commercial sector, a person of ordinary skill in the art can readily generate a DNA construct appropriate for  
20 establishing transgenic cells using the materials and methods described herein.

Transfection techniques are well known to a person of ordinary skill in the art and materials and methods for carrying out transfection of DNA constructs  
25 into cells are commercially available. Materials typically used to transfect cells with DNA constructs are lipophilic compounds, such as Lipofectin<sup>TM</sup> for example. Particular lipophilic compounds can be induced to form liposomes for mediating transfection of the DNA construct into the  
30 cells.

Target sequences from the DNA construct can be inserted into specific regions of the nuclear genome by rational design of the DNA construct. These design techniques and methods are well known to a person of  
35 ordinary skill in the art. See, for example, U.S. Pat. No. 5,633,067; U.S. Pat. No. 5,612,205 and WO93/22432, all of which are incorporated by reference herein in their

- 24 -

entirety. Once the desired DNA sequence is inserted into the nuclear genome, the location of the insertion region as well as the frequency with which the desired DNA sequence has inserted into the nuclear genome can be  
5 identified by methods well known to those skilled in the art.

Once the transgene is inserted into the nuclear genome of the donor somatic cell, that cell, like other donor somatic cells of the invention, can be used as a  
10 nuclear donor in the nuclear transfer methods disclosed herein. The means of transferring the nucleus of a somatic cell into the zona pellucida-free, enucleated oocyte preferably involves cell fusion to form a reconstituted cell.

15 Fusion is typically induced by application of a direct current (DC) electrical pulse across the contact/fusion plane, but additional alternating current (AC) may be used to assist alignment of donor and recipient cells. Electroporation produces a pulse of  
20 electricity that is sufficient to cause a transient breakdown of the plasma membrane and which is short enough that the membrane reforms rapidly. Thus, if two adjacent membranes are induced to breakdown and upon reformation the lipid bilayers intermingle, small channels will open  
25 between the two cells. Due to the thermodynamic instability of such a small opening, it enlarges until the two cells become one. Reference is made to U.S. Pat. No. 4,997,384 by Prather et al., (incorporated by reference in its entirety herein) for a further discussion of this  
30 process. A variety of electroporation media can be used including eg., sucrose, mannitol, sorbitol and phosphate buffered solution.

Fusion can also be accomplished using Sendai virus as a fusogenic agent (Graham, Wister Inot. Symp.  
35 Monogr., 9, 19, 1969). Fusion may also be induced by exposure of the cells to fusion-promoting chemicals, such as polyethylene glycol.



- 25 -

Preferably, the donor somatic cell and zona pellucida-free, enucleated oocyte are placed in a 500µm fusion chamber and covered with 4ml of 26°C-27°C fusion medium (0.3M mannitol, 0.1mM MgSO<sub>4</sub>, 0.05mM CaCl<sub>2</sub>). The  
5 cells are then electrofused by application of a double DC electrical pulse of 70-100V for about 15µs, approximately 1s apart. After fusion, the resultant fused reconstituted cells are then placed in a suitable medium until  
activation, eg., TCM-199 medium.

10 In a preferred method of cell fusion the donor somatic cell is firstly attached to the zona pellucida-free, enucleated oocyte. For example, a compound is selected to attach the somatic cell to the zona pellucida-free, enucleated oocyte to enable fusing of the somatic  
15 cell and zona pellucida-free, enucleated oocyte membranes. The compound may be any compound capable of agglutinating cells. The compound may be a protein or glycoprotein capable of binding or agglutinating carbohydrate. More preferably the compound is a lectin. The lectin may be  
20 selected from the group consisting of Concanavalin A, Canavalin A, Ricin, soybean lectin, lotus seed lectin and phytohemagglutinin (PHA). Preferably the compound is PHA.

Preferably the zona pellucida-free, enucleated oocytes are exposed to PHA before being contacted with a  
25 somatic cell. Preferably the zona pellucida-free, enucleated oocytes are exposed to a concentration of PHA in the range of 50 - 400µg/ml. Most preferably the concentration is about 200µg/ml. The zona pellucida-free, enucleated oocytes may be exposed to PHA from 1 - 60s.  
30 Most preferably the enucleated oocytes are exposed to PHA for 3s.

Following treatment with PHA, the zona pellucida-free, enucleated oocyte may be contacted with a somatic cell to attach said somatic cell to the zona pellucida-free, enucleated oocyte. The zona pellucida-free,  
35 enucleated oocyte may be contacted with a somatic cell by conventional methods known to those skilled in the field.

- 26 -

Preferably the zona pellucida-free, enucleated oocyte is contacted with a somatic cell by manipulation using a micropipette. The zona pellucida-free, enucleated oocyte and attached somatic cell then may be fused as described  
5 above.

In one preferred embodiment, the method of electrofusion described above also comprises a further fusion step, or the fusion step described above comprises one donor somatic cell and two or more zona pellucida-  
10 free, enucleated oocytes. The double fusion method has the advantageous effect of increasing the cytoplasmic volume of the reconstituted cell.

A reconstituted cell is typically activated by electrical and/or non-electrical means before, during,  
15 and/or after fusion of the nuclear donor and recipient oocyte (See, for example, Susko-Parrish et al., U.S. Pat. No. 5,496,720). Activation methods include:

- 1) . Electric pulses;
- 2) . Chemically induced shock;
- 20 3) . Penetration by sperm;
- 4) . Increasing levels of divalent cations in the oocyte by introducing divalent cations into the oocyte cytoplasm, eg., magnesium, strontium, barium or calcium, eg., in the form of an ionophore. Other methods of  
25 increasing divalent cation levels include the use of electric shock, treatment with ethanol and treatment with caged chelators; and

- 5) . Reducing phosphorylation of cellular proteins in the oocyte by known methods, eg., by the  
30 addition of kinase inhibitors, eg., serine-threonine kinase inhibitors, such as 6-dimethyl-aminopurine, staurosporine, 2-aminopurine, and sphingosine. Alternatively, phosphorylation of cellular proteins may be inhibited by introduction of a phosphatase into the  
35 oocyte, eg., phosphatase 2A and phosphatase 2B.

The reconstituted cell may also be activated by known methods. Such methods include, e.g., culturing the

- 27 -

reconstituted cell at sub-physiological temperature, in essence by applying a cold, or actually cool temperature shock to the reconstituted cell. This may be most conveniently done by culturing the reconstituted cell at  
5 room temperature, which is cold relative to the physiological temperature conditions to which embryos are normally exposed. Suitable oocyte activation methods are the subject of U.S. Pat. No. 5,496,720, to Susko-Parrish *et al.*, herein incorporated by reference in its entirety.

10 The activated reconstituted cells may then be cultured in a suitable in vitro culture medium until the generation of cells and cell colonies. Culture media suitable for culturing and maturation of embryos are well known in the art. Examples of known media, which may be  
15 used for bovine embryo culture and maintenance, include Ham's F-10 plus 10% FCS, TCM-199 plus 10% FCS, Tyrodes-Albumin-Lactate-Pyruvate (TALP), Dulbecco's Phosphate Buffered Saline (PBS), synthetic oviductal fluid ("SOF"), B2, CR1aa medium and high potassium simplex medium  
20 ("KSOM"), Eagle's and Whitten's media. One of the most common media used for the collection and maturation of oocytes is TCM-199, and 1 to 20% serum supplement including FCS, newborn serum, estrual cow serum, lamb serum or steer serum. A preferred maintenance medium  
25 includes TCM-199 with Earl salts, 10% FSC, 0.2mM Na pyruvate and 50µg/ml gentamicin sulphate. Any of the above may also involve co-culture with a variety of cell types such as granulosa cells, oviduct cells, BRL cells and uterine cells and STO cells.

30 Alternatively, in one preferred embodiment, there is provided a method of culturing a reconstituted cell (embryo) comprising

(i) inserting a desired somatic cell or cell nucleus into a zona pellucida-free, enucleated mammalian  
35 oocyte, under conditions suitable for the formation of a reconstituted cell;

(ii) activating the reconstituted cell

- 28 -

(iii) incubating and culturing one or more of said cells until embryos of greater than 2 cells develop.

Preferably, the embryos are cultured until greater than 60 cells. More preferably, between 60 to 200  
5 cells.

Briefly, the above method is described as the Well of Well (WOW) system. This method involves culturing reconstituted cells either individually or groups in small depressions ("V" or "U" shaped) made on the bottom of the  
10 dish by pressing the ground tip of "darning" type needles (such as the "Aggregation needles" manufactured and supplied by BLS Ltd., Budapest, Hungary, Catalogue no. DN-09) into the bottom of the culture dish, which is typically a 4 well "Nunclone" dish (Vajta et al, 2000.).  
15 These depressions (WOWs) are typically 0.5 to 2 mm deep and 0.5 to 2 mm in diameter at the top. After activation the embryos are placed into these WOW depressions, either individually, or 2 or 3 "reconstituted" nuclear transfer embryos can be placed together in each WOW and cultured as  
20 aggregates after activation (when they are still single cells, prior to cell division). Alternatively the reconstituted single cell nuclear transfer embryos can be cultured individually in the WOWs for 3 to 4 days (when they are typically between 8 and 128 cells) and then 2 or  
25 3 such embryos can be combined in single wells for further culture as "aggregates". Culturing nuclear transfer embryos as such aggregates, increases the cell numbers in the final embryos for transfer and increases pregnancy rates (Peura et al, 1998).

30 In one further embodiment, there is provided a method of culturing a reconstituted cell (embryo) comprising

providing a reconstituted cell (embryo) according to the methods as hereinbefore described in medium;

35 obtaining a tube having at least two open ends and wherein one end is capable of receiving the reconstituted cell (embryo), the tube having a diameter

- 29 -

capable of drawing and maintaining the reconstituted cell (embryo) in the medium in the tube;

drawing the reconstituted cell (embryo) into the tube; and

5 incubating and culturing the reconstituted cell (embryo) in the tube.

In the method of culturing in the tube, the tube is preferably of a grade which poses minimal toxicity to the embryo. Most preferably, it is uncoated or treated,  
10 acid washed borosilicate laboratory grade glass. Most importantly, the tube must have holding capacity such that the medium surrounding the embryo is held in the tube generally by capillary action and surface tension so as to maintain the embryo within the tube. The media is  
15 cushioned in the tube by an air/media interface from either end of the tube, and occasionally by a small plug of oil.

The tube of the culture system may be of any diameter providing that it can hold and maintain an embryo  
20 in the medium within the tube so that the embryo may develop within the drawn medium. Therefore, the tube must be capable of providing sufficient capillary action and surface tension to the medium to maintain the medium vertically within the tube and also to draw the embryo up  
25 the tube. Preferably, the tube has an internal diameter of 200-250mm. The tube may be a capillary tube. Narrower ranges of internal diameter may be in the order of 200mm or less with the size of an embryo being the limiting factor. Narrower ranges such as 200mm or less may be of  
30 benefit for full promotion of development.

The embryo may be drawn or taken up into the tube under passive capillary action or by an active pressure drawing the fluid up the tube. The second method may be employed providing the tube has sufficient capability to  
35 maintain and hold the medium and embryo in the tube.

Once the embryo is drawn into the tube, it is preferred that the tube is held vertically rather than

- 30 -

horizontally so as to create a cushion on the air/medium interface. Horizontal incubation may also be employed although the vertical orientation is most preferred.

The culture tube system is designed so that the embryo contained therein can develop to a further advanced stage of development, preferably to the mature blastocyst stage. However, any stages such as early cleavage or morula may be selected after observing the development of the embryo directly in the tube. The embryo can be removed at any time depending on the desired development stage. This has many advantages since the embryo, once contained and matured in the culture system, is immediately available with minimal manipulation for implantation into an animal at a suitable stage of development.

Afterward, the cultured reconstituted cell or embryos are preferably washed and then placed in a suitable media, eg., TCM-199 medium containing 10% FCS contained in well plates which preferably contain a suitable confluent feeder layer. Suitable feeder layers include, by way of example, fibroblasts and epithelial cells, eg., fibroblasts and uterine epithelial cells derived from ungulates, chicken fibroblasts, murine (e.g., mouse or rat) fibroblasts, STO and SI-m220 feeder cell lines, and BRL cells.

In one embodiment, the feeder cells comprise mouse embryonic fibroblasts. Preparation of a suitable fibroblast feeder layers are well known in the art.

The reconstituted cells are cultured on the feeder layer until the reconstituted cells reach a size suitable for transferring to a recipient female, or for obtaining cells which may be used to produce cells or cell colonies. Preferably, these reconstituted cells will be cultured until at least about 2 to 400 cells, more preferably about 4 to 128 cells, and most preferably at least about 50 cells. The culturing will be effected under suitable conditions, i.e., about 39°C. and 5% CO<sub>2</sub>, with the

- 31 -

culture medium changed in order to optimise growth typically about every 2-5 days, preferably about every 3 days.

The methods for embryo transfer and recipient animal management in the present invention are standard procedures used in the embryo transfer industry. Synchronous transfers are important for success of the present invention, i.e., the stage of the nuclear transfer embryo is in synchrony with the estrus cycle of the recipient female. This advantage and how to maintain recipients are reviewed in Siedel, G. E., Jr. ("Critical review of embryo transfer procedures with cattle" in *Fertilization and Embryonic Development in Vitro* (1981) L. Mastroianni, Jr. and J. D. Biggers, ed., Plenum Press, New York, N.Y., page 323), the contents of which are hereby incorporated by reference.

Briefly, blastocysts may be transferred non-surgically or surgically into the uterus of a synchronized recipient. Other medium may also be employed using techniques and media well-known to those of ordinary skill in the art. In one procedure, cloned embryos are washed three times with fresh KSOM and cultured in KSOM with 0.1% BSA for 4 days and subsequently with 1% BSA for an additional 3 days, under 5% CO<sub>2</sub>, 5% O<sub>2</sub> and 90% N<sub>2</sub> at 39°C. Embryo development is examined and graded by standard procedures known in the art. Cleavage rates are recorded on day 2 and cleaved embryos are cultured further for 7 days. On day seven, blastocyst development is recorded and one or two embryos, pending availability of embryos and/or animals, is transferred non-surgically into the uterus of each synchronized foster mother.

Foster mothers preferably are examined for pregnancy by rectal palpation or ultrasonography periodically, such as on days 40, 60, 90 and 120 of gestation. Careful observations and continuous ultrasound monitoring (monthly) preferably is made throughout pregnancy to evaluate embryonic loss at various stages of

- 32 -

gestation. Any aborted fetuses should be harvested, if possible, for DNA typing to confirm clone status as well as routine pathological examinations.

The reconstituted cell, activated reconstituted  
5 cell or embryo, fetus and animal produced during the steps of such method, and cells, nuclei, and other cellular components which may be harvested therefrom, are also asserted as embodiments of the present invention.

The present invention can also be used to produce  
10 embryos, fetuses or offspring which can be used, for example, in cell, tissue and organ transplantation. By taking a fetal or adult cell from an animal and using it in the cloning procedure a variety of cells, tissues and possibly organs can be obtained from cloned fetuses as  
15 they develop through organogenesis. Cells, tissues, and organs can be isolated from cloned offspring as well. This process can provide a source of "materials" for many medical and veterinary therapies including cell and gene therapy. If the cells are transferred back into the animal  
20 in which the cells were derived, then immunological rejection is averted. Also, because many cell types can be isolated from these clones, other methodologies such as hematopoietic chimerism can be used to avoid immunological rejection among animals of the same species as well as  
25 between species.

Throughout the description and claims of this specification, the word "comprise" and variations of the word, such as "comprising" and "comprises", is not intended to excluded other additives, components, integers or  
30 steps.

The discussion of prior art documents, acts, devices and the like is included in this specification solely for the purpose of providing a context for the present invention. It is not suggested or represented  
35 that any or all of these matters formed part of the prior art base or were common general knowledge in the field relevant to the present invention as it existed in



- 33 -

Australia before the filing date of this application.

The invention will now be further described by way of reference only to the following non-limiting examples. It should be understood, however, that the  
5 examples following are illustrative only, and should not be taken in any way as a restriction on the generality of the invention described above. For example, while the majority of the examples relate to bovine oocytes and granulosa cells, it is to be understood that the invention  
10 can also be applied to other animal oocytes as disclosed herein, including for example, sheep, goats and horses.

EXAMPLE 1                    METHODS OF NUCLEAR TRANSFER USING GRANULOSA CELLS AS DONORS

15                    Except where otherwise indicated all chemicals were obtained from Sigma Chemical Co. (St Louis, MO, USA).

                  In vitro maturation of bovine oocytes (a total of 150 per day) was performed as described in detail earlier (Vajta et al., 1996) with minor modifications. Briefly,  
20 oocytes were aspirated from abattoir-derived ovaries, matured in 4-well dishes (Nunc, Roskilde, Denmark) for 24h in bicarbonate buffered TCM-199 medium (Gibco BRL, Paisley, UK) supplemented with 15% cow serum, 10IU/ml pregnant mare serum gonadotropin and 5IU/ml human  
25 chorionic gonadotropin (Suigonan<sup>R</sup> Vet, Intervet, Australia) and were incubated under mineral oil at 39°C in 5% CO<sub>2</sub> in humidified air.

                  At 19h after the start of maturation cumulus cells were removed by vortexing. From this point (except  
30 where otherwise indicated) all manipulations were performed on a heated stage adjusted to 39°C. Mature oocytes (approximately 110) were selected according to the presence of the first polar body, placed for 5min into 0.5% pronase (Sigma protease) solution to remove the zona  
35 pellucida from the cells. Zona pellucida-free oocytes (approximately 50 to 60, half of the total) were lined up in a 35mm Petri dish (Falcon, Becton Dickinson Labware,

- 34 -

Franklin Lakes, NJ, USA) filled with 4ml of Hepes buffered TCM-199 medium (TCMH) supplemented with 20% FCS and 10µg/ml cytochalasin B (refer to Figure 1A).

Bisection was performed manually under  
5 stereomicroscopic control with Ultra sharp Splitting  
Blades (AB Technology, Pullman, WA, USA) (refer to Figure  
1B). Bisected oocytes (demi-oocytes) were then collected  
by swirling in the middle of the dish, placed into the  
same medium without cytochalasin and the procedure was  
10 repeated with the rest of the oocytes.

After completion of the bisection, all demi-  
oocytes were stained with the fluorochrome Hoechst 33342  
dissolved in TCMH and 30% FCS, then placed into 3µl drops  
of the same medium formed on the bottom of a 60mm Falcon  
15 petri dish and covered with oil (3 half-oocyte per drop, a  
total of approx. 70 drop). Following examination under  
inverted microscopy and ultraviolet illumination, demi-  
oocytes without chromatin staining (cytoplasts) were  
selected, collected under a stereomicroscope (a total of  
20 approximately 100 to 120) in one well of the original  
maturation dish under conditions described for maturation  
and incubated until fusion.

Somatic cells were prepared from granulosa cell  
monolayers formed in 4-well dishes used 7 to 10 days  
25 earlier for maturation. After 5min incubation in 100µl of  
0.05% trypsin, the well was filled with 800µl of TCMH and  
20% FCS, cells were separated by vigorous pipetting and  
stored in 1.5ml Eppendorf tubes at 4°C until fusion.

Fusions were performed at 21-22h after the start  
30 of maturation. For the first fusion, 15 enucleated  
oocytes were transferred into TCMH with 2% FCS. 5µl of  
the granulosa cell suspension was sedimented to the bottom  
of the middle section of a 4-well dish filled with TCMH  
without serum supplementation. Using a finely drawn mouth  
35 glass pipette enucleated oocytes were individually exposed  
for 3s to 200µg/ml of PHA (ICN Pharmaceuticals,  
Australia), then quickly dropped over a single granulosa

- 35 -

cell settled to the bottom of the dish (refer to Figures 1C and 1D). Following attachment the enucleated oocyte-granulosa cell pair was picked up again, and transferred to a fusion chamber covered with 4ml of 26-27°C fusion medium (0.3M mannitol, 0.1mM MgSO<sub>4</sub>, 0.05mM CaCl<sub>2</sub>). The fusion chamber contained parallel platinum wires with a diameter of 1mm and a separation of 0.8mm. Using an alternating current (AC) of 15V and 700KHz (Genaust Electrofusion Machine, Australia). The pair was attached to one wire (somatic cell furthest from the wire - refer to Figure 1E) then fused with a double DC pulse of 85V, each for 20µs, 0.1s apart. The pair was then carefully removed and incubated in TCM-199 and 20% FCS for 15 to 30min, when fusion was evaluated. After having fused all 15 enucleated oocytes with granulosa cells, fusion medium was exchanged, and new enucleated oocytes and granulosa cells were prepared for new series of first fusion.

For the second fusion, unfused enucleated oocytes and fused pairs (reconstituted cells) (5 to 10 of each) were first incubated in the fusion medium for 1 to 2min, then aligned in pair using the same AC pulse, unfused enucleated oocytes attaching the wire (refer to Figure 1F). A double fusion pulse with the same parameters, but with 45V DC was applied, then the double enucleated oocyte and granulosa cell triplets were incubated in TCMH and 20% FCS for 20min. Fused reconstituted cells (a total of approximately 40 to 45) were then transferred into a well of a maturation dish and incubated further under conditions described above (Vajta et al., 2002).

Activation was initiated 24 to 26h after the start of maturation (approx. 3h after the fusion). Reconstituted cells were first incubated in TCMH containing 10µM calcium ionophore A23187 for 5min in air, then in 2mM 6-dimethylaminopurine (6-DMAP) dissolve in bicarbonate-buffered TCM-199 supplemented with 10% FCS in 5% CO<sub>2</sub> in air for 5 hours.

Embryos were then repeatedly washed 400µl of

- 36 -

SOFaaci medium (Holm et al., 1999) supplemented with 5% cow serum and covered with mineral oil, then randomly distributed into three groups, each of the in the held in the same medium. The first group was individually  
5 cultured in 1µl drops covered with mineral oil. Embryos of the second group were placed in well of the wells (WOWs; Vajta et al., 2000). The third group was individually loaded into 2µl Drummond microcapillaries (Thouas et al., 2001). All cultures were performed at  
10 39°C, in 5% CO<sub>2</sub> and 90% N<sub>2</sub> (in humidified air).

Two and 7 days after reconstruction, cleavage and blastocyst per embryo rates were evaluated, respectively, under a stereomicroscope. Figure 1(G) shows a blastocyst developed in the GO system 7 days after fusion. Figure  
15 1(H) shows the same blastocyst after removal from the GO system. Some of the blastocysts were fixed for future immunohistochemical and ultrastructural investigations; others were vitrified for future embryo transfer experiments.

20 Statistical analysis of cleavage and blastocyst rates was performed using Pearson Chi-square method were  $P > 0.05$  was regarded as significant.

#### 25 EXAMPLE 2 RESULTS OF NUCLEAR TRANSFER USING GRANULOSA CELLS AS DONORS

The average efficiency of the main steps and the approximate time required in 7 replicate nuclear transfer experiments using a total of 1016 immature oocytes are summarised in Table 1.

- 37 -

TABLE 1AVERAGE EFFICIENCY AND APPROXIMATE REQUIRED TIME FOR STEPS  
OF ZONA-FREE SOMATIC CELL NUCLEAR TRANSFER

5

	Procedure	Individual	Cumulative	Time Required
		Efficiency	Efficiency	
10	PB rate determination	-	-	30min
	Zona removal	99%	99%	10min
	Bisection	89%	88%	20min
	UV investigation	91%	80%	30min
	First fusion	94%	75%	40min
15	Second fusion	91%	69%	15min
	(Related work)	-	-	35min
<hr/>				
Total				180 min

20

- 38 -

Oocytes without a well visible polar body (28% of the total) were discarded. However, this loss cannot be attributed to the nuclear transfer method itself; therefore these were not included in the calculation of efficiency. The losses during bisection are the result of lysis observed 5min after the completion of the procedure. The final accuracy of enucleated oocyte selection was close to 100%. However, a 9% difference mostly attributed to technical failures occurred between the calculated and obtained number. Losses during fusions were almost entirely results of lysis or technical failures, unsuccessful fusions (separated pairs 15-20min after fusion) were exceptional and usually eliminated with a repeated fusion step.

On average, 105 matured oocytes were used and 35 enucleated oocyte-enucleated oocyte-somatic cell triplets were produced per experiment, and the required time for the work did not exceed 3 hours.

Embryo development rates achieved in the three culture systems are summarised in Table 2. All values were significantly different except for cleavage rates (2-cells or more) for embryos cultured in microdrops versus the WOW system.

TABLE 2CLEAVAGE AND BLASTOCYST RATES ACHIEVED IN DIFFERENT  
CULTURE GROUPS

5

	<u>Culture system</u>	<u>Cleavage rate</u>	<u>Blastocyst rate</u>
	Microdrop	25/41 (61%) <sup>a</sup>	0/41 ( 0%) <sup>a</sup>
	WOW system	76/103 (74%) <sup>a</sup>	19/103 (18%) <sup>b</sup>
10	Go system	47/53 (89%) <sup>b</sup>	10/53 (36%) <sup>c</sup>

---

a, b, c Values with different superscripts in the same column mean significant difference.

- 40 -

Generally, embryos cultured in microdrops did not develop beyond the 8- to 16-cell stage; compaction occurred only in the WOW or GO system. Blastocyst formation usually started 6 days after the reconstruction and was completed on Day 7.

The efficiency of the preferred double fusion nuclear transfer method described in the Examples is possibly because the two cells being fused are close in size (in our experiments the cytoplasm volume is only half of that of the original oocyte), and the PHA adherence may establish strong membrane contacts on a relatively large area. In contrast to the single-step (enucleated oocyte + enucleated oocyte + blastomere) fusion method of Peura et al. (1998), the double fusion method (first enucleated oocyte + somatic cell to produce a reconstituted cell, then fusing a second enucleated oocyte with the reconstituted cell), describe in the Examples is more convenient and efficient. The use of two enucleated oocytes for reconstruction also means that the cytoplasm volume loss, which is an unavoidable part of the conventional nuclear transfer, can entirely be compensated.

The results of the preferred methods described in the Examples suggest that the methods have considerable potential for the development of cell cloning techniques that meet the requirements for automation of nuclear transfer for the large-scale application of these technologies in agriculture. In particular, the simplified method of somatic cell nuclear transfer greatly reduces reliance on the expensive and technically difficult micromanipulation methods presently used. Furthermore, these improvements have significantly reduced the overall time to conduct successful nuclear transfer.

### 35 EXAMPLE 3            SIMPLIFIED ZONA-FREE SOMATIC CELL CLONING TECHNIQUES

The protocols used in this Example were the same



- 41 -

as those described in Example 1, with the following exception.

Reconstituted nuclear transfer embryos were either cultured singly, or as aggregates of 2 reconstituted nuclear transfer embryos and culture was performed either in glass capillaries or in the WOWs, in 4 well Nunclone dishes. After activation the embryos were drawn into the glass tubes or placed into the WOW depressions, either individually, or alternatively, 2 "reconstituted " nuclear transfer embryos were cultured in each glass capillary, or in each WOW depression, and cultured as aggregates after activation.

Tables 3, 4 and 5 show the blastocyst development rates and pregnancy rates from the culture and a transfer of nuclear transfer embryos produced using the techniques described in Example 1. The reconstituted nuclear transfer embryos were cultured either individually (Table 3) or as aggregates of two reconstituted nuclear transfer embryos (Tables 4 and 5).

All experiments reported in Table 3 were performed using one week old granulosa cells except for the last one, where foetal fibroblasts were used. Blastocyst rates were from nuclear transfer embryos cultured singly (ie. not as aggregates).

Table 4 shows the blastocyst rates achieved from simplified, zona-free nuclear transfer techniques using transgenic donor cells (transfected with bovine  $\alpha$  S1 casein gene). Embryos were cultured as aggregates of 2 single reconstituted nuclear transfer embryos. Cultured in either GO or WOW system. Data are based per constructed embryo subjected to activation. The losses as the consequence of fusion and activation have been negligible. 20 to 30 blastocysts can be produced in 3.5 hours (plus activation).

Table 5 shows the pregnancy rates from the transfer of aggregated nuclear transfer embryos from simplified, zona pellucida-free nuclear transfer

- 42 -

techniques using transgenic donor cells (fibroblasts transfected with bovine  $\alpha$  S1 casein gene). Reconstituted nuclear transfer embryos were either cultured singly, or as aggregates of 2 and culture was performed either in  
5 glass capillaries (GO) or in WOWs in 4 well Nun dishes (Lewis et al., 2002).

- 43 -

TABLE 3BLASTOCYST RATES ACHIEVED 20001/2002

5	Date of Experiment	Cell Type	No. of single reconstituted NT embryos into culture	No blastocyst	%blastocyst
	05.12.01	granulosa	44	21	48%
10	12.12.01	granulosa	40	22	55%
	13.12.01	granulosa	59	38	64%
	14.12.01	granulosa	53	24	45%
	15.12.01	granulosa	54	23	43%
	25.01.02	granulosa	39	18	47%
15	26.01.02(IL)	granulosa	21	9	43%
	30.01.02(IL)	granulosa	19	9	47%
	05.02.02	fetal fibroblast	56	25	45%
<u>TOTAL</u>			<u>385</u>	<u>189</u>	<u>49%</u>

20

- 44 -

TABLE 4

	No. of single	No. of aggregates	No. blastocyst	%blastocyst
5	reconstituted NT			
	embryos into culture			
	180	90	35	39 % per
				aggregate
				or 19% per
10				single
				reconstituted
				NT embryo

- 45 -

TABLE 5

5 PREGNANCY RATES FROM SIMPLIFIED, ZONA-FREE NUCLEAR  
TRANSFER TECHNIQUES USING TRANSGENIC DONOR CELLS  
 (TRANSFECTED WITH BOVINE  $\alpha$  S1 CASEIN GENE).

10	Fresh or vitrified	No. of recipients receiving embryos (no. of embryos)	No. of recipients pregnant at 30-40 days (%)	No. pregnancies ongoing over 7 months
	- fresh	6 (19)	2 (33%)	1
	- vitrified	5 (16)	2 (40%)	1
15	<u>TOTAL</u>	<u>11 (35)</u>	<u>4 (36%)</u>	<u>2*</u>

\*1 pregnancy lost at 7.5 months (foetus not recovered).

\*1 pregnancy lost at 8 months and 1 week gestation.

20 Dystocia - foetus dead after veterinary assisted birth.  
 Calf birth weight 35kg. Post-mortem at VIAS, Attwood. No  
 significant gross abnormalities detected at P-M. On  
 histopathology, no significant lesions were observed in  
 the brain, thymus, lung, heart, liver, kidney, skeletal  
 25 muscle or placenta (see VIAS report 01-005483-MW)

- 46 -

EXAMPLE 4      IMPROVED IMPLANTATION FOLLOWING THE  
TRANSFER OF NUCLEAR TRANSFER EMBRYOS INTO  
RECIPIENT COWS.

The protocols used were as described in Example  
5 1, with the following exceptions.

The reconstituted single cell nuclear transfer  
embryos were cultured individually in the WOWs for 4 days  
(when they were typically between 30 and 60 cells) and  
then 2 such embryos were combined in single wells for  
10 further culture as "aggregates". Culturing nuclear  
transfer embryos as such aggregates, increases the cell  
numbers in the final embryos for transfer and increases  
pregnancy rates (Peura et al, 1998).

Six 7 day blastocysts were transferred into 6  
15 recipient cows. That is, only 1 embryo was transferred  
per recipient. Five of the 6 recipient cows were  
diagnosed pregnant (by ultrasonography) at around day 30  
of gestation. In contrast, in Examples 3 and 5 multiple  
embryos were transferred per recipient which increases  
20 pregnancy rates.

EXAMPLE 5      OPTIMISATION OF FUSION PARAMETERS  
AND CONDITIONS

In this example, research for optimising the  
25 fusion parameters and conditions was undertaken.  
Comparisons were made between fusing somatic cells with 2  
or 3 cytoplasts. After activation, reconstituted nuclear  
transfer embryos were cultured as single embryos, or as  
aggregates of 2 embryos.

30 The protocols used in this Example were the same  
as those used in Example 1, with the following exceptions:

1. A single step fusion was used to fuse the somatic cell  
and the 2 cytoplasts, instead of the 2 fusion steps used  
35 to achieve this end in Example 1.

Somatic cell and cytoplasts (either 2 or 3  
cytoplasts per somatic cell) were fused simultaneously.

- 47 -

Fibroblasts were used. Required parameters for fusion were calculated according to fibroblast size (Teissie et al., 1998). Either 2 V on the fibroblast surface (112 V = 2.22 kV) for 6  $\mu$ Sec (Genaust Electrofusion Machine, Australia) or 3 V on the fibroblast cell surface (166.8 V = .3 kV) for 4  $\mu$ Sec (BTX Electro Cell Manipulator 200, USA) employing fusion chamber with 0.5 mm gap. The induced potential difference being the steady state value in fibroblasts but will be a minute fraction of it with the larger cytoplasm therefore preserving the viability of cytoplasm. All fusions were performed using a single pulse.

One half cytoplasm was exposed to PHA and attached to the one fibroblast cell by manipulation using finely drawn pipette. Fibroblast/cytoplasm pairs together with another half cytoplasm (when triplets were made) were equilibrated in the electrofusion medium.

2. Either 2 or 3 cytoplasts were fused with the somatic cell to form the reconstituted nuclear transfer embryo.
3. After activation, nuclear transfer embryos were cultured either as single embryos or as aggregates of 2 reconstituted nuclear transfer embryos.

Seven pregnancies resulted from the transfer of a total of 60 embryos into 16 recipients receiving (ie. an average of 3.8 embryos were transferred per recipient) At the time of writing there are 3 ongoing pregnancies.

Table 6 compares the fusing 2 or 3 cytoplasts with a somatic cell. Single embryos were cultured in glass capillaries (GO system). Aggregated embryos were cultured in WOWs in 4 well Nunc dishes (2 reconstituted nuclear transfer embryos per WOW)

TABLE 6

	Single embryo in glass capillary		Aggregates (2 )embryos per WOW	
	2-cytoplasm	3-cytoplasm	2-cytoplasm	3-cytoplasm*
Blastocyst Rates	10.5% (24/228)	23.3% (7/30)	14.9% (30/189)	63.6% (35/55)

- 5 \*Fusions were Performed with BTX machine with predicted values (166 V for 4 $\mu$ Sec) while others were performed with GA machine (112 V for 6  $\mu$ Sec.). Reconstituted



- 49 -

Table 7 shows the number of transferred embryos  
and pregnancy rates

- 50 -

TABLE 7

Number of embryos transferred (derived from either single or aggregated reconstituted nuclear transfer embryos)

5

	No. of Embryos	No. of Recipient s	Pregnancy rate	Lost	Ongoing Pregnancies
Fresh	7	2	50.0% (1/2)	1	0
Cryo-preserved	53	14	42.9% (6/14)	3	3
Total	60	16	43.8% (7/16)	4	3

- 51 -

It was noted that less time was required time for the process. In particular, the number of steps (re-checking and re-fusion of SC-cytoplasm complex, 2<sup>nd</sup> fusion with another oocyte) have been cut down with optimised fusion  
5 parameters and conditions without sacrificing the efficiency, Fusion process can be completed in a very short time, however enucleation process still takes almost 60-70% of the time spent on the process. This will be the major target for automatisisation of the system.

10 Predicted voltages and pulse duration are efficient for simultaneous fusion. Predicted values (calculated according to 9µm fibroblast) were tested with BTX machine for simultaneous fusion of somatic cell + cytoplasm, fusion and blastocysts rates were determined.

15 Oocytes were not selected according to PB or morphological appearances since September in order to speed up to system. The same no selection criteria was applied to the transferred embryos.

PVA was added to fusion medium to prevent  
20 stickiness and membrane rupture of oocytes therefore lyses. Although it is suggested that fusion medium should be prepared every 2 weeks, medium was frozen in aliquots and no harmful effect was noted. Demo-oocytes were incubated in the separate well containing fusion medium  
25 before introducing into the fusion chamber.

Existing fusion protocol has been simplified and improved by introduction of a single step fusion. Somatic cell and cytoplasm are fused simultaneously (10-12 nuclear transfer at the same time) compared to existing  
30 two step protocol (somatic cell + cytoplasm and then cytoplasm + cytoplasm). Required time for existing protocol cut-down considerably.

Also fusion parameters were calculated and tested according to the existing formula (Teissie et al., 1997).  
35 Somatic cell and zona pellucida-free, enucleated oocytes were fused simultaneously (10-12 nuclear transfer at the same time). With the new parameters (3 V on the cell

- 52 -

surface for 4 $\mu$ Sec, the induced potential difference will be its steady state value in fibroblasts but will be a minute fraction of it with the larger cytoplasm and this will preserve the cell viability of this larger partner.

5

EXAMPLE 6                    NUCLEAR TRANSFER METHOD USING MURINE AND  
OVINE OOCYTES COMPARED TO BOVINE OOCYTES

The protocols shown in Example 1 were used in experiments with ovine and murine oocytes. For example,  
10 ovine and murine oocytes were harvested, treated to remove the zona pellucida and enucleated in a similar fashion to the bovine oocytes referred to in Example 1. The somatic cells used were fibroblasts.

Table 8 shows the fusion rates in reconstituted  
15 sheep embryos following simultaneous fusion of 2 cytoplasm and a somatic cell (fibroblast) at 55 V (1.1 kV) and 112 V (2.2 kV) for 6  $\mu$ Sec.

TABLE 8

FUSION RATES IN RECONSTITUTED ZONA PELLUCIDA-FREE  
OVINE EMBRYOS

5

Voltage	55 V (1.1 kV)	112 V (2.2 Kv)
Fusion Rates	30.7% (4/13)	61.5% (4/13)

- 54 -

Table 9 shows the fusion rates in reconstituted ovine embryos following simultaneous fusion of 2 cytoplasm and ovine somatic cell (fibroblast) at 112 V (2.2 kV) for 6  $\mu$ Sec in 2 replicates of experiments. No of chromatins  
5 in each embryo was checked 3 hours after fusion under the fluorescent microscope.

- 55 -

TABLE 9

CHROMATIN IN RECONSTITUTED ZONA PELLUCIDA-FREE OVINE  
EMBRYOS

5

Groups	% (No)
Control	10.0% (1/10)
Chromatin	64.1% (25/39)
Single Chromatin	58.9% (23/35)
Double Chromatin	5.70% (2/35)
No Chromatin	35.9% (14/39)

- 56 -

Table 10 shows the lyses rates of reconstituted sheep nuclear transfer embryos following simultaneous fusion of 2 cytoplasm and somatic cell (fibroblast) at 112 V (2.2 kV) for 6  $\mu$ Sec in 2 replicates of experiments



- 57 -

TABLE 10

LYSIS RATES OF RECONSTITUTED ZONA PELLUCIDA-FREE OVINE  
NUCLEAR TRANSFER EMBRYOS

5

Fusion Rates	% (no)
No oocytes	100% (138; expected demi oocytes=276)
Demi-oocytes	83.4% (231)
Lyses following splitting	16.3% (45)
No of cultured embryos	43

- 58 -

TABLE 11LYSIS FOLLOWING BISECTION OF ZONA PELLUCIDA-FREE MURINEOOCYTES

5

<u>Groups</u>	<u>% (No)</u>	<u>.</u>
No oocytes	100%	(36 expected demi
oocytes=72)		
Demi-oocytes	12.5%	(9)
10 Lyses following splitting	87.5	(63)



REFERENCES

- Colman, A (1999). Somatic cell nuclear transfer in mammals: progress and applications. *Cloning* 1: 185-200.
- Galli, C, Duchi, R Moor, RM and Lazzari, G.  
5 (1999). Mammalian leucocytes contains information necessary for the development of a new individual. *Cloning* 1: 161-170.
- Holm, P, Booth, PJ, Schmidt, MH, Greve, T and Callesen, H. (1999). High bovine blastocyst development in  
10 a static *in vitro* production system using SOFaa medium supplemented with sodium citrate and myo-inositol with or without serum-proteins. *Theriogenology*: 52, 683-700.
- Lewis, IM, Vajta, G, French, AJ, Hall, VJ, Korfiatis, NA, Ruddock, NT, Travers, MJ, Travers, RL and  
15 Trounson, AO. (2002). Pregnancy rates from simplified zona-free somatic cell cloning and traditional zona-enclosed cloning in cattle. *Theriogenology* 57, 431.
- Lewis, IM, Munsie, MJ, French, AJ, Daniels, R and Trounson, AO. (2001). The cloning cycle: from amphibia to  
20 mammals and back. *Reproductive Medicine Reviews* 9, 13-33.
- Peura, TT, Lane, M, Lewis, IM and Trounson, AO. (1998). The effect of recipient oocyte volume on nuclear transfer in cattle. *Mol. Reprod. Dev.* 50, 185-191.
- Teissie, J and Ramos, C. (1998). Correlation  
25 between electric field pulse induced long-lived permeabilization and fusogenicity in cell membranes. *Biophys. J.* 74:1889-98.
- Thouas, GA, Jones, GM and Trounson, AO. (2001). A novel method of micro-culture of mouse zygotes to the  
30 blastocyst stage - the "GO" culture system. *Human Reproduction* 16,168.
- Trounson, A. (2001). Nuclear transfer in human medicine and animal breeding. *Reprod. Fertil. Dev.* 13: 31-9.
- 35 Vajta G., Lewis IM, Korfiatis NA, Travers RL, Trounson AO. (2002). Bovine somatic cell cloning without micromanipulators: optimization of certain parameters.

- 61 -

*Theriogenology* 57, 453.

Vajta, G, Holm, P, Greve, T. and Callesen, H.  
(1996). Factors affecting survival rates of *in vitro*  
produced bovine embryos after vitrification and direct in-  
5 straw rehydration. *Theriogenology*, 45: 191-200.

Vajta, G, Peura, TT, Holm, P, Páldi, A, Greve, T  
and Trounson, AO and Callesen, H. (2000). New method for  
culture of zona-included or zona-free embryos: the Well of  
the Well (WOW) system. *Mol. Reprod. Dev.* 55: 256-254.

10 Wells, KD and Powell, AM. (2000). Blastomeres  
from somatic cell nuclear transfer embryos are not  
allocated randomly in chimeric blastocysts. *Cloning*, 2: 9-  
22.

23 FEB 2005

RECEIVED

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. A method of nuclear transfer comprising the step of transferring a somatic cell or somatic cell nuclei into a zona pellucida-free, enucleated oocyte, with the proviso that said method does not include a method of cloning human beings.
2. A method according to claim 1, wherein the oocytes are isolated from oviducts and/or ovaries of a non-human mammal.
3. A method according to claim 2, wherein the oocytes are isolated by oviductal recovery procedures or transvirginal recovery procedures.
4. A method according to claim 2, wherein the oocytes are isolated by aspiration.
5. A method according to claim 1, wherein the oocytes are at prophase I or metaphase II.
6. A method according to claim 5, wherein the oocytes are at prophase I.
7. A method according to claim 1, wherein the somatic cell, somatic cell nuclei and/or oocyte is isolated from an ungulate mammal selected from the group consisting of domestic or wild representatives of bovids, ovids, cervids, suids, equids and camelids.
8. A method according to claims 7, wherein the ungulate mammal is a cow or bull, bison, buffalo, sheep, big-horn sheep, horse, pony, donkey, mule, deer, elk, caribou, goat, water buffalo, camel, llama, alpaca or pig.
9. A method according to claim 7, wherein the bovid species is *Bos taurus*, *Bos indicus* or *Bos buffaloes* cows or

bulls.

10. A method according to claim 1, wherein the zona  
pellucida is removed by a method selected from the group  
5 consisting of physical manipulation, chemical treatment and  
enzymatic digestion.

11. A method according to claim 10, wherein the zona  
pellucida is removed by enzymatic digestion.  
10

12. A method according to claim 10, wherein the  
enzymatic digestion is by exposure to a protease, a pronase  
or a combination thereof.

13. A method according to claim 12, wherein the  
enzymatic digestion is by exposure to a pronase.  
15

14. A method according to claim 13, wherein the  
pronase is used at a concentration between 0.1 to 5%.  
20

15. A method according to claim 13, wherein the  
pronase is used at a concentration between 0.25% to 2%.

16. A method according to claim 13, wherein the  
pronase is used at a concentration of about 0.5%.  
25

17. A method according to claim 1, wherein the step  
of enucleation is by a method selected from the group  
consisting of aspiration, physical removal, use of DNA-  
30 specific fluorochromes, and irradiation with ultraviolet  
light.

18. A method according to claim 17, wherein the  
enucleation is by physical removal.  
35

19. A method according to claim 18, wherein the

physical removal is bisection.

20. A method according to claim 1, wherein the somatic cells are selected from the group consisting of  
5 epithelial cells, neural cells, epidermal cells, keratinocytes, hematopoietic cells, melanocytes, chondrocytes, lymphocytes (B and T lymphocytes), erythrocytes, macrophages, monocytes, mononuclear cells, fibroblasts, cardiac muscle cells, and other muscle cells.
- 10 21. A method according to claim 20, wherein the somatic cells are obtained from the group consisting of skin cells, lung cells, pancreatic cells, liver cells, stomach cells, intestinal cells, cardiac cells,  
15 reproductive organ cells, bladder cells, kidney cells, urethral cells and other urinary organ cells.
22. A method according to claim 21, wherein the somatic cells are fibroblast cells or granulosa cells.
- 20 23. A method according to claim 21, wherein the somatic cells are *in vitro* cultured fibroblast or granulosa cells.
- 25 24. A method according to claim 21, wherein the somatic cell is a transgenic cell.
25. A method according to claim 24, wherein the transgenic cell has been modified by insertion, deletion or  
30 modification of a desired gene or genes.
26. A method according to claim 1, wherein the step of transferring the somatic cell or nucleus is by fusion.
- 35 27. A method according to claim 26, wherein the method of fusion is selected from the group consisting of



chemical fusion, electrofusion and biofusion.

28. A method according to claim 27, wherein the chemical fusion or biofusion is accomplished by exposing  
5 the zona pellucida-free, enucleated oocyte and somatic cell combination to a fusion agent.

29. A method according to claim 28, wherein the fusion agent is any compound or biological organism that  
10 can increase the probability that portions of plasma membranes from different cells will fuse when a somatic cell donor is placed adjacent to a zona pellucida-free, enucleated oocyte recipient.

15 30. A method according to claim 29, wherein the fusion agents are selected from the group consisting of polyethylene glycol (PEG), trypsin, dimethylsulfoxide (DMSO), lectins, agglutinin, viruses, and Sendai virus.

20 31. A method according to claim 27, wherein the electrofusion is induced by application of an electrical pulse.

32. A method according to claim 31, wherein the  
25 electrofusion comprises the step of delivering one or more electrical pulses to the zona pellucida-free, enucleated oocyte and somatic cell combination.

33. A non-human mammal obtained by a method according  
30 to claim 1.

34. A cell, tissue or organ obtained from a non-human mammal according to claim 33.

35 35. A method for producing a genetically engineered or transgenic non-human mammal comprising the step of:

(i) inserting, removing or modifying a desired gene or genes in a non-human somatic cell or cell nucleus;

5           (ii) inserting the non-human somatic cell or cell nucleus into a zona pellucida-free, enucleated oocyte under conditions suitable for the formation of a reconstituted cell;

10           (iii) activating the reconstituted cell to form an embryo;

(iv) culturing said embryo until greater than the 2-cell developmental stage; and

15           (v) transferring said cultured embryo to a host mammal such that the embryo develops into a transgenic fetus.

36.           A method according to claim 35, wherein the  
20 oocytes are isolated from oviducts and/or ovaries of a non-human mammal.

37.           A method according to claim 36, wherein the  
25 oocytes are isolated by oviductal recovery procedures or transvirginal recovery procedures.

38.           A method according to claim 36, wherein the oocytes are isolated by aspiration.

30 39.           A method according to claim 36, wherein the oocytes are at prophase I or metaphase II.

40.           A method according to claim 36, wherein the oocytes are at prophase I.

35

41.           A method according to claim 36, wherein the

oocytes are matured to metaphase II by culturing *in vitro*.

42. A method according to claim 36, further comprising the step of cryopreserving the oocytes,  
5 reconstituted cell, embryo or fetus.

43. A method according to claim 36, wherein the somatic cell, somatic cell nuclei and/or oocyte is isolated from an ungulate mammal selected from the group consisting  
10 of domestic or wild representatives of bovids, ovids, cervids, suids, equids and camelids.

44. A method according to claims 43, wherein the ungulate mammal is a cow or bull, bison, buffalo, sheep,  
15 big-horn sheep, horse, pony, donkey, mule, deer, elk, caribou, goat, water buffalo, camel, llama, alpaca or pig.

45. A method according to claim 43, wherein the bovid species is *Bos taurus*, *Bos indicus* or *Bos buffaloes* cows or  
20 bulls.

46. A method according to claim 36, wherein the zona pellucida is removed by a method selected from the group consisting of physical manipulation, chemical treatment and  
25 enzymatic digestion.

47. A method according to claim 36, wherein the zona pellucida is removed by enzymatic digestion.

30 48. A method according to claim 47, wherein the enzymatic digestion is by exposure to a protease, a pronase or a combination thereof.

49. A method according to claim 48, wherein the  
35 enzymatic digestion is by exposure to a pronase.

50. A method according to claim 49, wherein the pronase is used at a concentration between 0.1 to 5%.

51. A method according to claim 49, wherein the  
5 pronase is used at a concentration between 0.25% to 2%.

52. A method according to claim 49, wherein the pronase is used at a concentration of about 0.5%.

10 53. A method according to claim 36, wherein the step of enucleation is by a method selected from the group consisting of aspiration, physical removal, use of DNA-specific fluorochromes, and irradiation with ultraviolet light.

15

54. A method according to claim 36, wherein the enucleation is by physical removal.

55. A method according to claim 54, wherein the  
20 physical removal is bisection.

56. A method according to claim 36, wherein the somatic cells are selected from the group consisting of epithelial cells, neural cells, epidermal cells,  
25 keratinocytes, hematopoietic cells, melanocytes, chondrocytes, lymphocytes (B and T lymphocytes), erythrocytes, macrophages, monocytes, mononuclear cells, fibroblasts, cardiac muscle cells, and other muscle cells.

30 57. A method according to claim 36, wherein the somatic cells are obtained from the group consisting of skin cells, lung cells, pancreatic cells, liver cells, stomach cells, intestinal cells, cardiac cells, reproductive organ cells, bladder cells, kidney cells,  
35 urethral cells and other urinary organ cells.

58. A method according to claim 57, wherein the somatic cells are fibroblast cells or granulosa cells.

59. A method according to claim 57, wherein the  
5 somatic cells are *in vitro* cultured fibroblast or granulosa cells.

60. A method according to claim 57, wherein the somatic cell is a transgenic cell.

10

61. A method according to claim 60, wherein the transgenic cell has been modified by insertion, deletion or modification of a desired gene or genes.

15 62. A method according to claim 36, wherein the step of transferring the somatic cell or nucleus is by fusion.

63. A method according to claim 62, wherein the method of fusion is selected from the group consisting of  
20 chemical fusion, electrofusion and biofusion.

64. A method according to claim 63, wherein the chemical fusion or biofusion is accomplished by exposing the zona pellucida-free, enucleated oocyte and somatic cell  
25 combination to a fusion agent.

65. A method according to claim 64, wherein the fusion agent is any compound or biological organism that can increase the probability that portions of plasma  
30 membranes from different cells will fuse when a somatic cell donor is placed adjacent to a zona pellucida-free, enucleated oocyte recipient.

66. A method according to claim 65, wherein the  
35 fusion agents are selected from the group consisting of polyethylene glycol (PEG), trypsin, dimethylsulfoxide

(DMSO), lectins, agglutinin, viruses, and Sendai virus.

67. A method according to claim 63, wherein the  
electrofusion is induced by application of an electrical  
5 pulse.

68. A method according to claim 67, wherein the  
electrofusion comprises the step of delivering one or more  
electrical pulses to the zona pellucida-free, enucleated  
10 oocyte and somatic cell combination.

69. A non-human mammal obtained by a method according  
to claim 36.

70. A cell, tissue or organ obtained from a non-human  
15 mammal according to claim 69.

71. A method according to claim 36, further  
comprising the step of fusing one or more further zona  
20 pellucida-free oocytes to the reconstituted cell.

72. A method according to claim 71, wherein the  
further step is undertaken sequentially or simultaneously  
with step (ii) of claim 36.

25 73. A method for cloning a non-human mammal  
comprising the steps of:

(i) inserting a desired non-human somatic cell  
30 or cell nucleus into a zona pellucida-free, enucleated  
oocyte, under conditions suitable for the formation of a  
reconstituted cell;

(ii) activating the reconstituted cell to form an  
35 embryo;

(iii) culturing said embryo until greater than the 2-cell developmental stage; and

(iv) transferring said cultured embryo to a host mammal such that the embryo develops into a fetus.

74. A method according to claim 73, wherein the oocytes are isolated from oviducts and/or ovaries of a non-human mammal.

10

75. A method according to claim 74, wherein the oocytes are isolated by oviductal recovery procedures or transvirginal recovery procedures.

15 76. A method according to claim 75, wherein the oocytes are isolated by aspiration.

77. A method according to claim 73, wherein the oocytes are at prophase I or metaphase II.

20

78. A method according to claim 73, wherein the oocytes are at prophase I.

79. A method according to claim 73, wherein the oocytes are matured to metaphase II by culturing *in vitro*.

25

80. A method according to claim 73, further comprising the step of cryopreserving the oocytes, reconstituted cell, embryo or fetus.

30

81. A method according to claim 73, wherein the somatic cell, somatic cell nuclei and/or oocyte is isolated from an ungulate mammal selected from the group consisting of domestic or wild representatives of bovids, ovids, cervids, suids, equids and camelids.

35

82. A method according to claims 81, wherein the ungulate mammal is a cow or bull, bison, buffalo, sheep, big-horn sheep, horse, pony, donkey, mule, deer, elk, caribou, goat, water buffalo, camel, llama, alpaca or pig.

5

83. A method according to claim 81, wherein the bovid species is *Bos taurus*, *Bos indicus* or *Bos buffaloes* cows or bulls.

10

84. A method according to claim 73, wherein the zona pellucida is removed by a method selected from the group consisting of physical manipulation, chemical treatment and enzymatic digestion.

15

85. A method according to claim 73, wherein the zona pellucida is removed by enzymatic digestion.

20

86. A method according to claim 85, wherein the enzymatic digestion is by exposure to a protease, a pronase or a combination thereof.

87. A method according to claim 86, wherein the enzymatic digestion is by exposure to a pronase.

25

88. A method according to claim 87, wherein the pronase is used at a concentration between 0.1 to 5%.

89. A method according to claim 87, wherein the pronase is used at a concentration between 0.25% to 2%.

30

90. A method according to claim 87, wherein the pronase is used at a concentration of about 0.5%.

35

91. A method according to claim 73, wherein the step of enucleation is by a method selected from the group consisting of aspiration, physical removal, use of DNA-

IPONZ  
20 OCT 2003

IPONZ  
20 OCT 2003



specific fluorochromes, and irradiation with ultraviolet light.

92. A method according to claim 73, wherein the  
5 enucleation is by physical removal.

93. A method according to claim 91, wherein the  
physical removal is bisection.

10 94. A method according to claim 73, wherein the  
somatic cells are selected from the group consisting of  
epithelial cells, neural cells, epidermal cells,  
keratinocytes, hematopoietic cells, melanocytes,  
chondrocytes, lymphocytes (B and T lymphocytes),  
15 erythrocytes, macrophages, monocytes, mononuclear cells,  
fibroblasts, cardiac muscle cells, and other muscle cells.

95. A method according to claim 73, wherein the  
somatic cells are obtained from the group consisting of  
20 skin cells, lung cells, pancreatic cells, liver cells,  
stomach cells, intestinal cells, cardiac cells,  
reproductive organ cells, bladder cells, kidney cells,  
urethral cells and other urinary organ cells.

25 96. A method according to claim 95, wherein the  
somatic cells are fibroblast cells or granulosa cells.

97. A method according to claim 95, wherein the  
somatic cells are *in vitro* cultured fibroblast or granulosa  
30 cells.

98. A method according to claim 95, wherein the  
somatic cell is a transgenic cell.

35 99. A method according to claim 98, wherein the  
transgenic cell has been modified by insertion, deletion or

modification of a desired gene or genes.

100. A method according to claim 73, wherein the step of transferring the somatic cell or nucleus is by fusion.

5

101. A method according to claim 100, wherein the method of fusion is selected from the group consisting of chemical fusion, electrofusion and biofusion.

10 102. A method according to claim 101, wherein the chemical fusion or biofusion is accomplished by exposing the zona pellucida-free, enucleated oocyte and somatic cell combination to a fusion agent.

15 103. A method according to claim 102, wherein the fusion agent is any compound or biological organism that can increase the probability that portions of plasma membranes from different cells will fuse when a somatic cell donor is placed adjacent to a zona pellucida-free,  
20 enucleated oocyte recipient.

104. A method according to claim 103, wherein the fusion agents are selected from the group consisting of polyethylene glycol (PEG), trypsin, dimethylsulfoxide  
25 (DMSO), lectins, agglutinin, viruses, and Sendai virus.

105. A method according to claim 103, wherein the electrofusion is induced by application of an electrical pulse.

30

106. A method according to claim 105, wherein the electrofusion comprises the step of delivering one or more electrical pulses to the zona pellucida-free, enucleated oocyte and somatic cell combination.

35

107. A non-human mammal obtained by a method according

to claim 73.

108. A cell, tissue or organ obtained from a non-human mammal according to claim 107.

5

109. A method according to claim 73, further comprising the step of fusing one or more further zona pellucida-free oocytes to the reconstituted cell.

10 110. A method according to claim 109, wherein the further step is undertaken sequentially or simultaneously with step (ii) of claim 73.

111. A method according to claim 73, wherein the step  
15 of activating the reconstituted cell is selected from the group consisting of electric pulse, chemical induced shock, penetration by sperm, increasing intracellular levels of divalent cations and reducing phosphorylation.

20 112. A method according to claim 73, wherein the fetus is transferred into the uterus of a synchronised recipient.

113. A method according to claim 112, wherein the recipient is a female non-human mammal.

25

114. A method for cloning a non-human mammal comprising the steps of:

(i) inserting a desired non-human somatic cell  
30 or cell nucleus into a first zona pellucida-free, enucleated mammalian oocyte, under conditions suitable for the formation of a reconstituted cell;

(ii) fusing a second or more oocyte to said  
35 reconstituted cell thereby increasing the cytoplasmic volume;

(iii) activating the reconstituted cell to form an embryo;

5 (iv) culturing said embryo until greater than the 2-cell developmental stage; and

(v) transferring said cultured embryo to a host mammal such that the embryo develops into a fetus.  
10

115. A method according to claim 114, wherein step (i) and step (ii) are undertaken sequentially or simultaneously.

15 116. A method according to claim 114, wherein step (i) and step (ii) are simultaneous.

117. A method according to claim 114, wherein the step of activating the reconstituted cell is selected from the  
20 group consisting of electric pulse, chemical induced shock, penetration by sperm, increasing intracellular levels of divalent cations and reducing phosphorylation.

118. A method according to claim 114, wherein the  
25 fetus is transferred into the uterus of a synchronised recipient.

119. A method according to claim 118, wherein the recipient is a female non-human mammal.

30 120. A method of culturing a reconstituted cell (embryo) comprising the steps of:

(i) inserting a desired non-human somatic cell  
35 or cell nucleus into a zona pellucida-free, enucleated oocyte, under conditions suitable for the formation of a

23 FEB 2005

RECEIVED

-77-

reconstituted cell (embryo);

(ii) activating the reconstituted cell;

5 (iii) incubating and culturing one or more of said  
cells until embryos of between 8 to 128 cells develop.

121. A method according to claim 120, wherein two or  
more cells are cultured together.

10

122. A method according to claim 120, wherein two or  
three cells are cultured together.

123. A method according to claim 120, wherein single  
15 reconstituted cells are cultured until embryos of between 8  
to 128 cells are produced and then 2 or more embryos are  
combined and cultured together as aggregates.

124. A method of nuclear transfer comprising the steps of:  
20 attaching a somatic cell or somatic cell nuclei to  
a zona pellucida-free, enucleated oocyte;  
transferring said somatic cell or somatic cell  
nuclei into the zona pellucida-free, enucleated oocyte, with  
the proviso that said method does not include a method of  
25 cloning human beings.

125. A method for producing a genetically engineered  
or transgenic non-human mammal comprising:

30 (i) inserting, removing or modifying a desired  
gene or genes in a non-human somatic cell or cell nucleus;

(ii) attaching the somatic cell or cell nucleus  
to a zona pellucida-free, enucleated oocyte and inserting  
35 said somatic cell or cell nucleus into said oocyte under  
conditions suitable for the formation of a reconstituted

cell;

(iii) activating the reconstituted cell to form an embryo;

5 (iv) culturing said embryo until greater than the 2-cell developmental stage; and

(v) transferring said cultured embryo to a host mammal such that the embryo develops into a transgenic  
10 fetus.

126. A method for cloning a non-human mammal comprising the steps of:

15 (i) attaching and inserting a desired non-human somatic cell or cell nucleus into a zona pellucida-free, enucleated oocyte, under conditions suitable for the formation of a reconstituted cell;

20 (ii) activating the reconstituted cell to form an embryo;

(iii) culturing said embryo until greater than the 2-cell developmental stage; and  
25

(iv) transferring said cultured embryo to a host mammal such that the embryo develops into a fetus.

127. A method according to claim 124, wherein the  
30 oocytes are isolated from oviducts and/or ovaries of a non-human mammal.

128. A method according to claim 127, wherein the  
35 oocytes are isolated by oviductal recovery procedures or transvirginal recovery procedures.

129. A method according to claim 127, wherein the oocytes are isolated by aspiration.

130. A method according to claim 124, wherein the  
5 oocytes are at prophase I or metaphase II.

131. A method according to claim 130, wherein the oocytes are at prophase I.

10 132. A method according to claim 125, wherein the oocytes are matured to metaphase II by culturing *in vitro*.

133. A method according to claim 125, further comprising the step of cryopreserving the oocytes,  
15 reconstituted cell, embryo or fetus.

134. A method according to claim 125, wherein the mammal is an ungulate selected from the group consisting of domestic or wild representatives of bovids, ovids, cervids,  
20 suids, equids and camelids.

135. A method according to claim 125, wherein the mammal is a cow or bull, bison, buffalo, sheep, big-horn sheep, horse, pony, donkey, mule, deer, elk, caribou, goat,  
25 water buffalo, camel, llama, alpaca or pig.

136. A method according to claim 135, wherein the bovid species is *Bos taurus*, *Bos indicus* or *Bos buffaloes* cows or bulls.  
30

137. A method according to claim 125, wherein the zona pellucida is removed by a method selected from the group consisting of physical manipulation, chemical treatment and enzymatic digestion.  
35

138. A method according to claim 137, wherein the zona

pellucida is removed by enzymatic digestion.

139. A method according to claim 138, wherein the enzymatic digestion is by exposure to a protease, a pronase  
5 or a combination thereof.

140. A method according to claim 139, wherein the enzymatic digestion is by exposure to a pronase.

10 141. A method according to claim 140, wherein the pronase is used at a concentration between 0.1 to 5%.

142. A method according to claim 140, wherein the pronase is used at a concentration between 0.25% to 2%.  
15

143. A method according to claim 140, wherein the pronase is used at a concentration of about 0.5%.

144. A method according to claim 140, wherein the step  
20 of enucleation is by a method selected from the group consisting of aspiration, physical removal, use of DNA-specific fluorochromes, and irradiation with ultraviolet light.

25 145. A method according to claim 144, wherein the enucleation is by physical removal.

146. A method according to claim 145, wherein the physical removal is bisection.  
30

147. A method according to claim 140, wherein the somatic cells are selected from the group consisting of epithelial cells, neural cells, epidermal cells, keratinocytes, hematopoietic cells, melanocytes,  
35 chondrocytes, lymphocytes (B and T lymphocytes), erythrocytes, macrophages, monocytes, mononuclear cells,



fibroblasts, cardiac muscle cells, and other muscle cells.

148. A method according to claim 147, wherein the somatic cells are obtained from the group consisting of skin cells, lung cells, pancreatic cells, liver cells, stomach cells, intestinal cells, cardiac cells, reproductive organ cells, bladder cells, kidney cells, urethral cells and other urinary organ cells.

10 149. A method according to claim 147, wherein the somatic cells are fibroblast cells or granulosa cells.

150. A method according to claim 147, wherein the somatic cells are *in vitro* cultured fibroblast or granulosa cells.

151. A method according to claim 147, wherein the somatic cell is a transgenic cell.


20 152. A method according to claim 151, wherein the transgenic cell has been modified by insertion, deletion or modification of a desired gene or genes.

25 153. A method according to claim 140, wherein the step of transferring the somatic cell or nucleus is by fusion.

154. A method according to claim 153, wherein the method of fusion is selected from the group consisting of chemical fusion, electrofusion and biofusion.

30 155. A method according to claim 154, wherein the chemical fusion or biofusion is accomplished by exposing the zona pellucida-free, enucleated oocyte and somatic cell combination to a fusion agent.

35 156. A method according to claim 155, wherein the



fusion agent is any compound or biological organism that can increase the probability that portions of plasma membranes from different cells will fuse when a somatic cell donor is placed adjacent to a zona pellucida-free, enucleated oocyte recipient.

157. A method according to claim 156, wherein the fusion agents are selected from the group consisting of polyethylene glycol (PEG), trypsin, dimethylsulfoxide (DMSO), lectins, agglutinin, viruses, and Sendai virus.

158. A method according to claim 155, wherein the electrofusion is induced by application of an electrical pulse.


159. A method according to claim 155, wherein the electrofusion comprises the step of delivering one or more electrical pulses to the zona pellucida-free, enucleated oocyte and somatic cell combination.

160. A method according to claim 124, wherein the step of attaching said somatic cell or cell nucleus is by exposure of the zona pellucida-free, enucleated oocyte to a compound capable of agglutinating cells.

161. A method according to claim 160, wherein the compound is a protein or glycoprotein capable of binding or agglutinating carbohydrate.

162. A method according to claim 161, wherein the compound is a lectin.

163. A method according to claim 162, wherein the lectin is selected from the group consisting of Concanavalin A, Canavalin A, Ricin, soybean lectin, lotus seed lectin and phytohemagglutinin (PHA).



164. A method according to claim 163, wherein the compound is PHA.

5 165. A method according to claim 164, wherein the zona pellucida-free, enucleated oocytes are exposed to PHA before being contacting with a somatic cell.

10 166. A method according to claim 163, wherein the zona pellucida-free, enucleated oocytes are exposed to a concentration of PHA in the range of 50 - 400 $\mu$ g/ml.

15 167. A method according to claim 166, wherein the concentration is about 200 $\mu$ g/ml.

168. A method according to claim 164, wherein the zona pellucida-free, enucleated oocytes are exposed to PHA from 1 - 60s.

20 169. A method according to claim 168, wherein the enucleated oocytes are exposed to PHA for 3s.

25 170. A method according to claim 125, further comprising the step of fusing one or more further zona pellucida-free oocytes to the reconstituted cell.

30 171. A method according to claim 170, wherein the further step is undertaken sequentially or simultaneously with step (ii) of claim 125.

172. A method for cloning a non-human mammal comprising the steps of:

35 (i) attaching and inserting a desired non-human somatic cell or cell nucleus into a first zona pellucida-free, enucleated mammalian oocyte, under conditions

suitable for the formation of a reconstituted cell;

(ii) fusing a second or more oocyte to said reconstituted cell thereby increasing the cytoplasmic  
5 volume;

(iii) activating the reconstituted cell to form an embryo;

10 (iv) culturing said embryo until greater than the 2-cell developmental stage; and

(v) transferring said cultured embryo to a host mammal such that the embryo develops into a fetus.  
15

173. A method according to claim 172, wherein step (i) and step (ii) are undertaken sequentially or simultaneously.

20 174. A method according to claim 172, wherein step (i) and step (ii) are simultaneous.

175. A method according to claim 125, wherein the step of activating the reconstituted cell is selected from the  
25 group consisting of electric pulse, chemical induced shock, penetration by sperm, increasing intracellular levels of divalent cations and reducing phosphorylation.

176. A method according to claim 125, wherein the  
30 fetus is transferred into the uterus of a synchronised recipient.

177. A method according to claim 176, wherein the recipient is a female mammal.

35 178. A method of culturing a reconstituted cell

23 FEB 2005

RECEIVED

- 85 -

(embryo) comprising

5 (i) attaching and inserting a desired non-human somatic cell or cell nucleus into a zona pellucida-free, enucleated oocyte, under conditions suitable for the formation of a reconstituted cell (embryo);

(ii) activating the reconstituted cell;

10 (iii) incubating and culturing one or more of said cells until embryos of between 8 to 128 cells develop, with the proviso that said method does not include a method of cloning human beings.

179. A method according to claim 178, wherein two or more cells are cultured together.

15

180. A method according to claim 178, wherein two or three cells are cultured together.

20 181. A method according to claim 178, wherein single reconstituted cells are cultured until embryos of between 8 to 128 cells are produced and then 2 or more embryos are combined and cultured together as aggregates.

25 182. A non-human mammal obtained by a method according to claim 124.

189. A cell, tissue or organ obtained from a non-human mammal according to claim 182.

- 190. A method according to claim 1 substantially as herein described or exemplified.
- 191. A non-human mammal according to claim 33 substantially as herein described or exemplified.
- 192. A cell, tissue or organ according to claim 34 substantially as herein described or exemplified.
- 193. A method according to claim 35 substantially as herein described or exemplified.
- 194. A non-human mammal according to claim 69 substantially as herein described or exemplified.
- 195. A cell, tissue or organ according to claim 70 substantially as herein described or exemplified.
- 196. A method according to claim 73 substantially as herein described or exemplified.
- 197. A non-human mammal according to claim 107 substantially as herein described or exemplified.
- 198. A cell, tissue or organ according to claim 108 substantially as herein described or exemplified.
- 199. A method according to claim 114 substantially as herein described or exemplified.

**IPONZ**  
**20 OCT 2003**


23 FEB 2005

RECEIVED

- 87 -

- 200. A method according to claim 120 substantially as herein described or exemplified.
- 201. A method according to claim 124 substantially as herein described or exemplified.
- 202. A method according to claim 125 substantially as herein described or exemplified.
- 203. A method according to claim 126 substantially as herein described or exemplified.
- 204. A method according to claim 172 substantially as herein described or exemplified.
- 205. A method according to claim 178 substantially as herein described or exemplified.
- 206. A non-human mammal according to claim 182 substantially as herein described or exemplified.
- 207. A cell, tissue or organ according to claim 189 substantially as herein described or exemplified.

Figure 1





**END**